var docs;if (!docs) docs =[]; docs["39"]={"3900":"<p><b>Title</b> Insulins / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of insulin if a beta-blocker is initiated/dose increased, or decreased effects if a beta-blocker is discontinued/dose decreased. Cardioselective beta-blockers may be safer than nonselective beta-blockers. <b>Note:</b> Cardioselectivity is dose-related, and any beta-blocker can cause problems. Instruct patients that tachycardia, as a sign of hypoglycemia, may not be present. The risk associated with ophthalmic beta-blockers is probably less than that associated with systemic agents. Ophthalmic beta-blockers are not likely of any concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Reports have demonstrated varying interactions between beta-blockers and insulin. Decreased blood glucose concentrations normally cause glucose mobilization from the liver via stimulation of epinephrine release. Nonselective beta-blockade inhibits this action, delaying recovery from hypoglycemia.<sup>1,2,3,4</sup> Epinephrine-induced tachycardia associated with hypoglycemia is inhibited by beta-blockers (probably all agents in class).<sup>1,2,3</sup> Further, epinephrine-related vasoconstriction (alpha effect) is unopposed in the peripheral vasculature as its vasodilation (beta<sub>2</sub>) effect is inhibited by nonselective beta-blockers, resulting in hypertension. Selective beta-blockers would exhibit this same property at higher doses.<sup>3,4,5</sup> Finally, the release of insulin from the pancreas in response to increased blood glucose concentrations (a beta<sub>2</sub> effect) may be inhibited by beta-blockers (especially nonselective agents).<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Deacon SP, Karuanayake A, and Barnett D, “Acebutolol, Atenolol, and Propranolol and Metabolic Responses to Acute Hypoglycaemia in Diabetics,” <i>Br Med J</i>, 1977, 2:1255-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=338101\">[PubMed 338101]</a></p>\n<p>2. Deacon SP and Barnett D, “Comparison of Atenolol and Propranolol During Insulin-Induced Hypoglycaemia,” <i>Br Med J</i>, 1976, 2:272-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8184\">[PubMed 8184]</a></p>\n<p>3. Ostman J, Arner P, Haglund K, et al, “Effect of Metoprolol and Alprenolol on the Metabolic, Hormonal, and Haemodynamic Response to Insulin-Induced Hypoglycaemia in Hypertensive, Insulin-Dependent Diabetics,” <i>Acta Med Scand</i>, 1982, 211:381-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7051762\">[PubMed 7051762]</a></p>\n<p>4. McMurtry RJ, “Propranolol, Hypoglycemia, and Hypertensive Crisis,” <i>Ann Intern Med</i>, 1974, 80:669-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4823826\">[PubMed 4823826]</a></p>\n<p>5. Shepherd AM, Lin MS, and Keeton TK, “Hypoglycaemia-Induced Hypertension in a Diabetic Patient on Metoprolol,” <i>Ann Intern Med</i>, 1981, 94:357-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7224384\">[PubMed 7224384]</a></p>\n<p>6. Mills GA and Horn JR, “Beta-Blockers and Glucose Control,” <i>DICP</i>, 1985, 19:246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2861072\">[PubMed 2861072]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3902":"<p><b>Title</b> Deferasirox / Aluminum Hydroxide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of aluminum hydroxide with deferasirox. Consider using antacids that do not contain aluminum.</p> \n<p><b>Discussion</b> Deferasirox prescribing information warns that the affinity of the drug for aluminum, although lower than that for iron, still may be sufficient to disrupt the efficacy of the drug.<sup>1</sup> Concurrent use of this combination should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3903":"<p><b>Title</b> DOXOrubicin (Conventional) / SORAfenib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SORAfenib may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of doxorubicin during concomitant sorafenib therapy.</p> \n<p><b>Discussion</b> The AUC of doxorubicin (60 mg/m<sup>2</sup> every 3 weeks) was increased 35% in 4 patients receiving sorafenib (400 mg twice daily).<sup>1</sup> In another study, doxorubicin maximum concentration and AUC were both significantly increased following concomitant doxorubicin (60 mg/m<sup>2</sup>) and sorafenib (400mg twice daily), but this interaction was seen only using the sorafenib 50mg tablets, and interestingly, not using the 200mg tablets, even at the same dose (nonsignificant decrease in maximum concentration, and no change in AUC).<sup>2</sup> Additionally, lower doses of sorafenib were studied (100mg and 200mg twice daily), with no significant interactions found at either dose. No significant increase in toxicity was noted for any dose studied. Of note, in the discussion of this study, it is mentioned that the 50mg tablets are no longer being studied.<br><br>The mechanism and clinical implications of this pharmacokinetic alteration are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Richly H, Kupsch P, Passage K, et al, “A Phase I Clinical and Pharmacokinetic Study of the Raf Kinase Inhibitor (RKI) BAY 43-9006 Administered in Combination with Doxorubicin in Patients with Solid Tumors,” <i>Int J Clin Pharmacol Ther</i>, 2003, 41(12):620-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14692720\">[PubMed 14692720]</a></p>\n<p>2. Richly H, Henning BF, Kupsch P, et al, “Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Doxorubicin in Patients with Refractory Solid Tumors,” <i>Ann Oncol</i>, 2006, 17:866-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16500908\">[PubMed 16500908]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3909":"<p><b>Title</b> Hydroxyurea / Didanosine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Didanosine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Hydroxyurea may enhance the adverse/toxic effect of Didanosine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to an increased risk of serious adverse events including hepatotoxicity, pancreatitis, and/or peripheral neuropathy, concomitant use of didanosine and hydroxyurea (with or without stavudine) should be avoided.</p> \n<p><b>Discussion</b> Didanosine prescribing information states that combined use with hydroxyurea should be avoided due to an increased risk of serious toxicity (pancreatitis, hepatotoxicity, peripheral neuropathy) with concomitant use (with or without concurrent stavudine).<sup>1</sup> Although the hydroxyurea prescribing information also warns about the potential risks with this combination, it only recommends avoidance of the three-drug combination of hydroxyurea, stavudine, and didanosine, recommending that patients using the combination of hydroxyurea and didanosine (without stavudine) be closely monitored for signs and symptoms of pancreatitis, and that the combination should be permanently discontinued in patients who develop pancreatitis.<sup>2,3</sup><br><br>Supporting papers related to an increased incidence of neuropathy, or case reports of pancreatitis, have also been published.<sup>4,5,6,7,8,9</sup> An analysis of data from 2613 patients treated with nucleoside reverse transcriptase inhibitors (NRTIs), consisting of 4311 person-years of follow-up data and 33 cases of pancreatitis, found a significantly increased relative risk of pancreatitis associated with the didanosine-hydroxyurea combination (RR=8.56, 95% CI: 1.85-39.49).<sup>9</sup> An approximate 2-fold increase in relative risk was associated with both didanosine-stavudine and didanosine-stavudine-hydroxyurea combinations, but the risk was not statistically significant for either combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Videx EC (didanosine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; November 2011.</p>\n<p>2. Hydrea (hydralazine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2016.</p>\n<p>3. Droxia (hydralazine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2016.</p>\n<p>4. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. <i>AIDS</i>. 2000;14(3):273-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10716503\">[PubMed 10716503]</a></p>\n<p>5. Rutschmann OT, Vernazza PL, Bucher HC, et al. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. <i>AIDS</i>. 2000;14(14):2145-2151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11061656\">[PubMed 11061656]</a></p>\n<p>6. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. <i>AIDS</i>. 2001;15(11):1379-1388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11504959\">[PubMed 11504959]</a></p>\n<p>7. Longhurst HJ, Pinching AJ. Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine. <i>BMJ</i>. 2001;322(7278):81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11154621\">[PubMed 11154621]</a></p>\n<p>8. Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. <i>J Acquir Immune Defic Syndr</i>. 2005;39(2):159-166. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15905731\">[PubMed 15905731]</a></p>\n<p>9. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. <i>AIDS</i>. 2001;15(5):617-620. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11316999\">[PubMed 11316999]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3910":"<p><b>Title</b> Abatacept / Anti-TNF Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of anti-TNF agents and abatacept due to an increased risk for serious infection. Monitor patients closely for signs of infection when transitioning from one teatment type to the other.</p>\n<div>\n <p><b>Anti-TNF Agents Interacting Members</b> Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, InFLIXimab, Lenalidomide, Pomalidomide, Thalidomide</p>\n</div> \n<p><b>Discussion</b> Abatacept prescribing information reports that concomitant administration of abatacept with anti-TNF agents resulted in a significantly higher rate of serious infections compared to anti-TNF agents alone (4.4% vs. 0.8%, respectively).<sup>1</sup> The same studies failed to demonstrate therapeutic advantages of concomitant therapy and as a result, the manufacturer of abatacept recommends against concomitant use with anti-TNF agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Orencia (abatacept). Princeton, NJ: Bristol-Myers Squibb, April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3911":"<p><b>Title</b> Thrombolytic Agents / Aprotinin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aprotinin may diminish the therapeutic effect of Thrombolytic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of thrombolytic agents in the presence of aprotinin.</p>\n<div>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> Aprotinin, via inhibition of plasmin, attenuates fibrinolysis.<sup>1</sup> It is possible, therefore, for aprotinin to antagonize the activity of fibrinolytic agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Trasylol [package insert]. West Haven, CT: Bayer HealthCare, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3912":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monior clinical response to thiazide diuretics when initiating or increasing the dose of nonsteroidal antiinflammatory drugs (NSAIDs). Patients should also be monitored closely for evidence of acute kidney injury (AKI) with this combination, particularly if also used together with an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blockers (ARB) as the use of such a three-drug combination may convey a particularly high risk for AKI.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Studies of the possible interaction between nonsteroidal antiinflammatory drugs (NSAIDs) and thiazide diuretics have yielded mixed results. Two studies in hypertensive patients have reported significant increases in systolic (approximate increase of 4 mmHg) and diastolic (approximate increase of 2 mmHg) blood pressure with ibuprofen (1800-2400 mg/day) or naproxen (375 mg/day) added to hydrochlorothiazide.<sup>1,2</sup> Another study in healthy volunteers showed that both diclofenac (50 mg) and rofecoxib (25 mg) significantly impaired the diuretic and natriuretic effect of hydrochlorothiazide.<sup>3</sup> Conversely, numerous other small studies in patients with hypertension have concluded that NSAIDs have relatively little<sup>4,5</sup> or no significant effect<sup>6,7,8</sup> on blood pressure response to thiazide diuretics (either alone or when combined with an ACE inhibitor).<br><br>Given the interaction between NSAIDs and loop diuretics, the variable findings of thiazide-NSAID interaction studies suggest that these agents interact in a unique mechanism. Several authors of the negative interaction studies have suggested that the apparent absence of a significant interaction indicates that thiazide-mediated changes in blood pressure are not prostaglandin-dependent, minimizing the potential for an NSAID interaction,<sup>6,7,8</sup> an explanation supported by findings from an earlier study in healthy volunteers.<sup>9</sup> Animal data suggest that any interaction that does exist is likely the result of NSAID-related impairment in chloride delivery to the distal tubule, which is the primary site where thiazides exert their effects.<sup>10</sup><br><br>The findings of several case-control and cohort studies suggest that the risk for acute kidney injury (AKI) may also be increased with concurrent use of an NSAID and a diuretic, and that the risk may be particularly high with use of the three drug combination of an angiotensin converting enzyme (ACE) inhibitor/angiotensin receptor blocker, diuretic, and NSAID,<sup>11,12,13,14</sup> and higher than that observed with any single drug or two drug combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gurwitz JH, Everitt DE, Monane M, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. <i>J Gerontol A Biol Sci Med Sci</i>. 1996;51(2):M74-M79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8612107\">[PubMed 8612107]</a></p>\n<p>2. Klassen D, Goodfriend TL, Schuna AA, Young DY, Peterson CA. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. <i>J Clin Pharmacol</i>. 1993;33(10):971-978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8227469\">[PubMed 8227469]</a></p>\n<p>3. Knauf H, Bailey MA, Hasenfuss G, Mutschler E. The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. <i>Eur J Clin Pharmacol</i>. 2006;62(11):885-892. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16964522\">[PubMed 16964522]</a></p>\n<p>4. Wright JT, McKenney JM, Lehany AM, Bryan DL, Cooper LW, Lambert CM. The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide. <i>Clin Pharmacol Ther</i>. 1989;46(4):440-444. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2791446\">[PubMed 2791446]</a></p>\n<p>5. Koopmans PP, Thien T, Gribnau FW. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. <i>Eur J Clin Pharmacol</i>. 1987;31(5):553-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3549320\">[PubMed 3549320]</a></p>\n<p>6. Gerber JG, LoVerde M, Byyny RL, Nies AS. The antihypertensive efficacy of hydrochlorothiazide is not prostacyclin dependent. <i>Clin Pharmacol Ther</i>. 1990;48(4):424-430. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225702\">[PubMed 2225702]</a></p>\n<p>7. Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. <i>Am J Hypertens</i>. 1999;12(9 Pt 1):925-928. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10509552\">[PubMed 10509552]</a></p>\n<p>8. Bhagat K. Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. <i>East Afr Med J</i>. 2001;78(10):507-509. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11921591\">[PubMed 11921591]</a></p>\n<p>9. Favre L, Glasson P, Riondel A, Vallotton MB. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. <i>Clin Sci (Lond)</i>. 1983;64(4):407-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6337769\">[PubMed 6337769]</a></p>\n<p>10. Kirchner KA, Brandon S, Mueller RA, Smith MJ, Bower JD. Mechanism of attenuated hydrochlorothiazide response during indomethacin administration. <i>Kidney Int</i>. 1987;31(5):1097-1103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3599650\">[PubMed 3599650]</a></p>\n<p>11. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. <i>Nefrologia</i>. 2015;35(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26300514\">[PubMed 26300514]</a></p>\n<p>12. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. <i>Kidney Int</i>. 2015;88(2):396-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25874600\">[PubMed 25874600]</a></p>\n<p>13. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. <i>Ren Fail</i>. 2014;36(7):1166-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24826803\">[PubMed 24826803]</a></p>\n<p>14. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299844\">[PubMed 23299844]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3913":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Aprotinin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aprotinin may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use caution when administering aprotinin to patients receiving angiotensin-converting enzyme inhibitors (ACEI) for blood pressure control. Monitor for reduced effects of the ACEI during and following the aprotinin infusion.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Infusion of aprotinin is reported to reduce the effect of captopril on both systolic and diastolic blood pressure.<sup>1,2,3</sup> These data suggest a role of the kallikrein-kinin system in the antihypertensive action of captopril (and, possibly all angiotensin-converting enzyme inhibitors. The effects only appear to be notable during the infusion of aprotinin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aguglia F and Santucci A, “Effect of Indomethacin and Trasylol on Captopril's Action: Preliminary Results,” <i>Drugs Exptl Clin Res</i>, 1980, 6:553-6.</p>\n<p>2. Overlack A, Stumpe KO, Kuhnert M, et al, “Evidence for Participation of Kinins in the Antihypertensive Effect of Converting Enzyme Inhibition,” <i>Klin Wochenschr</i>, 1981, 59(2):69-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6163004\">[PubMed 6163004]</a></p>\n<p>3. Mimran A, Targhetta R, and Laroche B, “The Antihypertensive Effect of Captopril: Evidence for an Influence of Kinins,” <i>Hypertension</i>, 1980, 2(6):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6161895\">[PubMed 6161895]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3914":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Cyclobenzaprine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cyclobenzaprine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of cyclobenzaprine and MAO inhibitors. A 14-day (minimum) washout period should be employed between the discontinuation of one agent the initiation of the other. Monitor for signs and symptoms of serotonin syndrome during the transition.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The literature contains many reports of symptoms resembling the serotonin syndrome that have occurred in patients receiving concomitant monoamine oxidase inhibitor (MAOI) and tricyclic antidepressant (TCA) therapy. At times, the therapies were not concomitant, but one may have been started subsequent to discontinuing the other without an adequate washout period.<sup>1,2,3,4,5,6,7,8,9,10,11</sup> Noting that cyclobenzaprine is structurally similar to tricyclic antidepressants, the manufacturer contraindicates their concomitant use.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brachfeld J, Wirtschafter A, and Wolfe S, “Imipramine-Tranylcypromine Incompatibility. Near Fatal Toxic Reaction,” <i>JAMA</i>, 1963, 186:1172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14063404\">[PubMed 14063404]</a></p>\n<p>2. Graham PM, Potter JM, and Paterson JW, “Combination Monoamine Oxidase Inhibitor/Tricyclic Antidepressant Interaction,” <i>Lancet</i>, 1982, ii:440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6124828\">[PubMed 6124828]</a></p>\n<p>3. Bowen LW, “Fatal Hyperpyrexia With Antidepressant Drugs,” <i>Br Med J</i>, 1964, 2:1465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14209383\">[PubMed 14209383]</a></p>\n<p>4. Nierenberg DW and Semprebon M, “The Central Nervous System Serotonin Syndrome,” <i>Clin Pharmacol Ther</i>, 1993, 53:84-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8257462\">[PubMed 8257462]</a></p>\n<p>5. Stern TA, Schwartz JH, and Shuster JL, “Catastrophic Illness Associated With the Combination of Clomipramine, Phenelzine and Chlorpromazine,” <i>Ann Clin Psychiatry</i>, 1992, 4:81-5.</p>\n<p>6. Tackley RM and Tregaskis B, “Fatal Disseminated Intravascular Coagulation Following a Monoamine Oxidase Inhibitor/Tricyclic Interaction,” <i>Anaesthesia</i>, 1987, 42:760-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3631476\">[PubMed 3631476]</a></p>\n<p>7. Brodribb TR, Downey M, and Gilbar PJ, “Efficacy and Adverse Effects of Moclobemide,” <i>Lancet</i>, 1994, 343:475-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7905963\">[PubMed 7905963]</a></p>\n<p>8. Spigset O, Mjorndal T, and Lovheim O, “Serotonin Syndrome Caused by a Moclobemide-Clomipramine Interaction,” <i>Br Med J</i>, 1993, 306:248. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8443525\">[PubMed 8443525]</a></p>\n<p>9. Francois B, Marquet P, Desachy A, et al, “Serotonin Syndrome Due to an Overdose of Moclobemide and Clomipramine. A Potentially Life-Threatening Association,” <i>Intensive Care Med</i>, 1997, 23:122-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9037653\">[PubMed 9037653]</a></p>\n<p>10. Ferrer-Dufol A, Perez-Aradros C, and Murillo EC, “Fatal Serotonin Syndrome Caused by Moclobemide-Clomipramine Overdose,” <i>Clin Toxicol</i>, 1998, 36:31-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9541038\">[PubMed 9541038]</a></p>\n<p>11. Kane FJ and Freeman D, “Nonfatal Reaction to Imipramine-MAOI Inhibitor Combination,” <i>Am J Psychiatry</i>, 1963, 120:79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14030577\">[PubMed 14030577]</a></p>\n<p>12. Ponto LB, Perry PJ, Liskow BI, et al, “Drug Therapy Reviews: Tricyclic Antidepressant and Monoamine Oxidase Inhibitor Combination Therapy,” <i>Am J Hosp Pharm</i>, 1977, 34:954 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=333909\">[PubMed 333909]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3917":"<p><b>Title</b> CYP2C8 Substrates (High risk with Inhibitors) / CYP2C8 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Moderate) Interacting Members</b> Clopidogrel, Deferasirox, Leflunomide, Teriflunomide</p>\n <p><b>CYP2C8 Substrates (High risk with Inhibitors) Interacting Members</b> Amiodarone, Amodiaquine, Dabrafenib, Dasabuvir, Enzalutamide, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Pioglitazone, Repaglinide, Rosiglitazone, Selexipag</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3918":"<p><b>Title</b> CYP2C8 Substrates (High risk with Inhibitors) / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n <p><b>CYP2C8 Substrates (High risk with Inhibitors) Interacting Members</b> Amiodarone, Amodiaquine, Dabrafenib, Dasabuvir, Enzalutamide, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Pioglitazone, Repaglinide, Rosiglitazone, Selexipag</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph will probably reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3919":"<p><b>Title</b> CYP2C9 Substrates (High risk with Inhibitors) / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n <p><b>CYP2C9 Substrates (High risk with Inhibitors) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin</p>\n</div> \n<p><b>Discussion</b> The CYP inhibitors in this monograph may reduce the metabolism of the substrates of this pathway. Substrate clearance would decrease and serum concentrations would increase. Increased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant increase in serum concentration of the substrate (ie, &gt; twofold) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3922":"<p><b>Title</b> Digoxin / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin levels/effects with conivaptan initiation/dose increase. Conversely, monitor for decreased digoxin levels/effects with conivaptan discontinuation/dose decrease.</p> \n<p><b>Discussion</b> Concomitant administration of digoxin (0.5 mg) and oral conivaptan (40 mg twice daily) increased digoxin AUC and Cmax 43% and 79% respectively, and decreased digoxin clearance by 30%.<sup>1</sup> The mechanism for this pharmacokinetic effect is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescrbing information. Vaprisol (conivaptan). Deerfield, IL: Astellas Pharma US, Inc, 05/2010</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3923":"<p><b>Title</b> Warfarin / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concomitant administration of warfarin (25 mg single dose) with conivaptan (40 mg daily x 4 days) was associated with an average 14% and 17% increase in S-warfarin AUC and maximum serum concentration, respectively.<sup>1</sup> INR and prothrombin time values were reportedly unaffected, though this study did use only a single dose of warfarin making the significance of these pharmacodynamic findings less clear.<br><br>The presumed mechanism for an interaction between conivaptan and warfarin would be conivaptan inhibition of the CYP3A-mediated metabolism of R-warfarin, which is mediated by CYP3A and several other cytochromes P450. However, the observed increase in S-warfarin concentrations is less expected since CYP2C9 is primarily responsible for its metabolism, and conivaptan is not known to inhibit CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vaprisol (conivaptan). Deerfield, IL: Astellas Pharma US, Inc., 05/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3924":"<p><b>Title</b> Ranolazine / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors, including azole antifungals.<sup>1</sup> Monitor for increased effects of ranolazine during concomitant use.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exceptions</b> Fluconazole, Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> Plasma concentrations of ranolazine (1000 mg twice daily) were increased more than threefold in normal subjects when coadministered with ketoconazole (200 mg twice daily).<sup>2</sup> Ketoconazole likely inhibited the CYP3A4-mediated metabolism of ranolazine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa [package insert]. Palo Alto, CA: CV Therapeutics, Inc, 2006.</p>\n<p>2. Jerling M, Huan BL, Leung K, et al, “Studies to Investigate the Pharmacokinetic Interactions Between Ranolazine and Ketoconazole, Diltiazem, or Simvastatin During Combined Administration in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2005, 45(4):422-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15778423\">[PubMed 15778423]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3925":"<p><b>Title</b> Ranolazine / Calcium Channel Blockers (Nondihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.</p>\n<div>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> DilTIAZem*, Verapamil*<br><b>Exception</b> Bepridil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Plasma concentrations of ranolazine (1000 mg twice daily) were increased approximately 2-fold in healthy volunteers when coadministered with diltiazem (180 mg to 360 mg daily).<sup>2</sup> There was evidence of dose-dependence as well, with ranolazine AUC increasing 52% with diltiazem 180mg/day, 93% with diltiazem 240mg/day, and 139% with diltiazem 360mg/day.<sup>2</sup> Similar changes were seen with verapamil (120 mg three times daily).<sup>1</sup> These calcium channel blockers likely inhibited the CYP3A4-mediated metabolism of ranolazine. Ranolazine (1000 mg twice daily) did not affect the pharmacokinetics of diltiazem (60 mg three times daily) in healthy volunteers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ranexa (ranolazine). Palo Alto, CA: CV Therapeutics, Inc., March 2009.</p>\n<p>2. Jerling M, Huan BL, Leung K, et al, “Studies to Investigate the Pharmacokinetic Interactions Between Ranolazine and Ketoconazole, Diltiazem, or Simvastatin During Combined Administration in Healthy Subjects,” <i>J Clin Pharmacol</i>, 2005, 45(4):422-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15778423\">[PubMed 15778423]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3926":"<p><b>Title</b> Simvastatin / Ranolazine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ranolazine may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the concurrent use of ranolazine with simvastatin when possible. If used together, avoid doses of simvastatin greater than 20 mg/day, and monitor closely for signs of HMG-CoA reductase inhibitor toxicity (eg, myositis, rhabdomyolysis). Rhabdomyolysis has been reported with concomitant use of these two agents.</p> \n<p><b>Discussion</b> According to ranolazine prescribing information, plasma concentrations of simvastatin (80 mg daily) and its active metabolite were increased approximately 2-fold when coadministered with ranolazine (1000 mg twice daily) in a study of healthy volunteers.<sup>1</sup> One case report describes a 63 year old male stable on simvastatin (80 mg daily) who developed rhabdomyolysis after initiating ranolazine (500 mg daily),<sup>2</sup> and another describes a 56 year old male also stable on simvastatin (40 mg daily) who similarly developed rhabdomyolysis after initiation of ranolazine (500 mg daily), diltiazem (60 mg twice/day), and carvedilol (12.5 mg twice/day).<sup>3</sup> Based on such data supporting this interaction and evidence that increased simvastatin concentrations are associated with a signficant increase in the risk for adverse muscle effects, simvastatin prescribing information recommends limiting the simvastatin dose to no more than 20 mg/day when used with ranolazine.<sup>4</sup> An American Heart Association scientific statement similarly recommends limiting the dose of lovastatin or simvastatin to a maximum of 20 mg/day with concurrent use of amlodipine.<sup>5</sup><br><br>The exact mechanism for this potential interaction is uncertain but might involve competition for CYP3A as both simvastatin and ranolazine are substrates of the isoenzyme. Ranolazine is also a known inhibitor of p-glycoprotein, suggesting that p-glycoprotein inhibition may also have contributed to the apparent interaction. Authors of the described case reports<sup>2,3</sup> acknowledge that underlying comorbidities and/or polypharmacy may have contributed to the onset of rhabdomyolysis. In contrast to ranolazine influence on simvastatin, simvastatin (20 to 80 mg daily) did not affect the serum concentrations of ranolazine.<sup>1,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; January 2016.</p>\n<p>2. Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. <i>Am J Health Syst Pharm</i>. 2010;67(1):1829-1831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20966146\">[PubMed 20966146]</a></p>\n<p>3. Rifkin SI. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. <i>Medscape J Med</i>. 2008;10(11):264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19099014\">[PubMed 19099014]</a></p>\n<p>4. Zocor (simvastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; February 2015.</p>\n<p>5. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>6. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. <i>J Clin Pharmacol</i>. 2005;45(4):422-433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15778423\">[PubMed 15778423]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3927":"<p><b>Title</b> Digoxin / Ranolazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ranolazine may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased levels/effects of digoxin during concurrent therapy with ranolazine. Decreased dosages of digoxin may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ranolazine prescribing information, ranolazine (1,000 mg twice daily) increased the digoxin (0.125 mg daily) serum concentration 1.5-fold in a study of healthy volunteers.<sup>1</sup> <br><br>Ranolazine prescribing information states that coadministration of ranolazine and digoxin results in increased exposure to digoxin.<sup>1</sup> Digoxin serum concentrations should be monitored during concomitant use and the dose of digoxin may have to be adjusted.<sup>1</sup><br><br>The mechanism of this interaction is likely due to ranolazine-mediated inhibition of P-glycoprotein, a transporter responsible for digoxin disposition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3928":"<p><b>Title</b> SUNItinib / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of sunitinib if coadministered with azole antifungals. Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n</div> \n<p><b>Discussion</b> The AUC of sunitinib was increased 51% in normal subjects when coadministered with ketoconazole.<sup>1</sup> Inhibition of the CYP3A4-mediated metabolism of sunitinib is the probable mechanism of this pharmacokinetic effect. Concurrent use with itraconazole is not recommended per itraconazole labeling.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sutent (sunitinib) [pprescribing information]. New York, NY: Pfizer Inc; April 2015.</p>\n<p>2. Sporanox (itraconazole) [pprescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3930":"<p><b>Title</b> Zidovudine / Emtricitabine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Emtricitabine may increase the serum concentration of Zidovudine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of zidovudine (300 mg daily) was increased 13% when coadministered with emtricitabine (200 mg daily) for 7 days.<sup>1</sup> No changes in the pharmacokinetics of zidovudine were noted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3932":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects (and, possible toxicity) of nonsteroidal anti-inflammatory agents during concomitant use with probenecid. The manufacturer of ketorolac contraindicates its use with probenecid.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal*, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin*, Ketoprofen*, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Probenecid has been shown to increase serum concentrations of several nonsteroidal anti-inflammatory agents from 50% to more than 200%.<sup>1,2,3,4,5,6,7,8</sup> Associated toxicities have been noted in some cases. The manufacturer of ketorolac, whose AUC (based on a single 10 mg dose) was increased more than 200% during concomitant use of probenecid (500 mg four times daily for 4 days), contraindicates their use.<sup>7</sup> These drugs may compete, or mutually inhibit, renal transport proteins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Macdonald JI, Wallace SM, Herman RJ, et al, “Effect of Probenecid on the Formation and Elimination Kinetics of the Sulphate and Glucuronide Conjugates of Diflunisal,” <i>Eur J Clin Pharmacol</i>, 1995, 7(6):519-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7768255\">[PubMed 7768255]</a></p>\n<p>2. Skeith MD, Simkin PA, and Healey LA, “The Renal Excretion of Indomethacin and Its Inhibition by Probenecid,” <i>Clin Pharmacol Ther</i>, 1968, 9(1):89-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5638099\">[PubMed 5638099]</a></p>\n<p>3. Baber N, Halliday L, Sibeon R, et al, “The Interaction Between Indomethacin and Probenecid. A Clinical and Pharmacokinetic Study,” <i>Clin Pharmacol Ther</i>, 1978, 24(3):298-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688724\">[PubMed 688724]</a></p>\n<p>4. Sinclair H and Gibson T, “Interaction Between Probenecid and Indomethacin,” <i>Br J Rheumatol</i>, 1986, 25(3):316-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3730746\">[PubMed 3730746]</a></p>\n<p>5. Foster RT, Jamali F, and Russell AS, “Pharmacokinetics of Ketoprofen Enantiomers in Cholecystectomy Patients: Influence of Probenecid,” <i>Eur J Clin Pharmacol</i>, 1989, 37(6):589-94. [PubMed2612555 ]</p>\n<p>6. Upton RA, Williams RL, Buskin JN, et al, “Effects of Probenecid on Ketoprofen Kinetics,” <i>Clin Pharmacol Ther</i>, 1982, 31(6):705-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075118\">[PubMed 7075118]</a></p>\n<p>7. Toradol [package insert]. Nutley, NJ: Roche Pharmaceuticals, 2002.</p>\n<p>8. Runkel R, Mroszczak E, Chaplin M, et al, “Naproxen-Probenecid Interaction,” <i>Clin Pharmacol Ther</i>, 1978, 24(6):706-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=710028\">[PubMed 710028]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3933":"<p><b>Title</b> Ropivacaine / Propofol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Propofol may increase the serum concentration of Ropivacaine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for ropivacaine-associated toxicity during concomitant use of propofol.</p> \n<p><b>Discussion</b> Ropivacaine is primarily metabolized via CYP1A2, and (in the absence of 1A2) 3A4.<sup>1</sup> Propofol is a weak inhibitor of CYP1A2, and therefore might increase the AUC of ropivacaine during concomitant use. Additionally, an in vitro study demonstrated competitive inhibition of the CYP3A4-mediated metabolism of ropivacaine by propofol (IC50 34.9 microM).<sup>2</sup> Concomitant use of these products could result in ropivacaine toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Naropin [package insert]. Wilmington, DE: AstraZeneca, 2004.</p>\n<p>2. Osaka Y, Inomata S, Tanaka E, et al, “Effect of Propofol on Ropivacaine Metabolism in Human Liver Microsomes,” <i>J Anesth</i>, 2006, 20(1):60-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16421682\">[PubMed 16421682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3935":"<p><b>Title</b> Anti-inhibitor Coagulant Complex (Human) / Antifibrinolytic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of anti-inhibitor coagulant complex and antifibrinolytic agents.</p>\n<div>\n <p><b>Antifibrinolytic Agents Interacting Members</b> Aminocaproic Acid, Aminomethylbenzoic Acid, Tranexamic Acid</p>\n</div> \n<p><b>Discussion</b> Prescribing information for both tranexamic acid and aminocaproic acid caution against concurrent use with anti-inhibitor coagulant concentrate due to the potential for an increased thrombosis risk.<sup>1,2</sup> Concern also exists regarding the potential development of disseminated intravascular coagulation or thrombosis during the concomitant use of anti-inhibitor coagulant complex and antifibrinolytic agents.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aminocaproic acid. Marietta, GA: VersaPharm Incorporated, 04/01.</p>\n<p>2. Prescribing information. Cyklokapron (tranexamic acid). New York, NY: Pfizer Inc, December 2008.</p>\n<p>3. Mannucci PM, Federici F, Vigano S, et al, “Multiple Dental Extractions with a New Prothrombin Complex Concentrate in Two Patients with Factor VIII Inhibitors,” <i>Thromb Res</i>, 1979, 15:359-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=494151\">[PubMed 494151]</a></p>\n<p>4. Jones ML, Wight J, Paisley S, et al, “Control of Bleeding in Patients with Haemophilia A with Inhibitors: A Systematic Review,” <i>Haemophilia</i>, 2003, 9:464-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12828680\">[PubMed 12828680]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3936":"<p><b>Title</b> Sirolimus / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of these drugs is contraindicated according to voriconazole prescribing information; however, case reports describe the successful management of this interaction with 50-90% reductions in sirolimus dose.</p> \n<p><b>Discussion</b> The AUC of sirolimus (2 mg single dose) was increased approximately 11-fold in healthy subjects when administered following 8 days of voriconazole (400 mg every 12 hours day 1, then 200 mg every 12 hours).<sup>1</sup> Several case reports also describe adverse effects, increased sirolimus concentrations, and/or decreased dose requirements with concurrent voriconazole.<sup>2,3,4,5</sup> This combination is listed as contraindicated in voriconazole prescribing information.<sup>1</sup> Of note, several reports have documented the safe use of this combination with 50-90% reductions in the sirolimus dose.<sup>2,3,5</sup><br><br>The likely mechanism of this interaction is voriconazole inhibition of the CYP3A4-mediated metabolism and/or p-glycoprotein transport of sirolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vfend (voriconazole). New York, NY: Pfizer Inc, March 2008.</p>\n<p>2. Surowiec D, DePestel DD, Carver PL, “Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management,” <i>Pharmacotherapy</i>, 2008, 28:719-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18503400\">[PubMed 18503400]</a></p>\n<p>3. Marty FM, Lowry CM, Cutler CS, et al, “Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation,” <i>Biol Blood Marrow Transplant</i>, 2006, 12:552-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16635790\">[PubMed 16635790]</a></p>\n<p>4. Sadaba B, Campanero MA, Quetglas EG, et al, “Clinical Relevance of Sirolimus Drug Interactions in Transplant Patients,” <i>Transplant Proc</i>, 2004, 36:3226-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15686733\">[PubMed 15686733]</a> </p>\n<p>5. Mathis AS, Shah NK, Friedman GS, “Combined Use of Sirolimus and Voriconazole in Renal Transplantation: A Report of Two Cases,” <i>Transplant Proc</i>, 2004, 36:2708-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15621130\">[PubMed 15621130]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3939":"<p><b>Title</b> Ferric Gluconate / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> During the administration of ferric gluconate patients should be monitored for the development of a variety of adverse effects, including nausea, vomiting, and hypotension. It is possible that patients receiving angiotensin-converting enzyme inhibitors may manifest exaggerated effects.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Case reports. Three enalapril-treated patients experienced a seeming exaggeration of side effects to IV ferric gluconate administration (eg, erythema, abdominal cramps, nausea, vomiting, hypotension).<sup>1</sup> During the 13-month period in which the 3 incidences occurred, 15 other patients received IV ferric gluconate without problem. None of the 15 were receiving an angiotensin-converting enzyme inhibitor. Another case series of patients (n=308) receiving both IV ferric gluconate and an angiotensin-converting enzyme inhibitor did not identify any apparent negative interactions between these products.<sup>2</sup> A mechanism for this apparent interaction (ie, the augmentation of ferric gluconate adverse effects) is unknown. The authors of the former report suggest that enalapril might exaggerate the known potential side effects of intravenous iron by inhibiting the degradation of the presumed inflammatory mediators of the iron-related effects (kinins: bradykinin, substance P).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rolla G, Bucca C, and Brussino L, “Systemic Reactions to Intravenous Iron Therapy in Patients Receiving Angiotensin-Converting Enzyme Inhibitor,” <i>J Allergy Clin Immunol</i>, 1994, 93:1074-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8006314\">[PubMed 8006314]</a></p>\n<p>2. Warnock DG, Adkinson F, Coyne DW, et al, “ACE Inhibitors and Intravenous Sodium Ferric Gluconate Complex in Sucrose (SFGC): Lack of Any Significant Interaction,” <i>J Am Soc Nephrol</i>, 2000, 11:170A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3942":"<p><b>Title</b> Niacin / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of niacin are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Niacin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Approximately 98% of niacin was bound to colestipol in an <i>in vitro</i> study.<sup>1</sup> A much lower amount (10% to 30%) was bound to cholestyramine.<sup>1</sup> The effect colesevelam is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niaspan [package insert]. Cranbury, NJ: Kos Pharmaceuticals, 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3943":"<p><b>Title</b> Raloxifene / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Raloxifene. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.<sup>1</sup> The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The absorption of raloxifene (single dose) was decreased 60% when coadministered with cholestyramine.<sup>1</sup> The effect of other bile acid sequestrants is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3944":"<p><b>Title</b> OLANZapine / LamoTRIgine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LamoTRIgine may enhance the sedative effect of OLANZapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased sedation, and other signs of CNS depression, during concomitant administration of lamotrigine and olanzapine.</p> \n<p><b>Discussion</b> The AUC of lamotrigine (50 mg/day) was unchanged in 14 normal subjects when coadministered with olanzapine (5 mg).<sup>1</sup> Both of these agents undergo glucuronidation. Mild sedation occurred during coadministration of these agents.<sup>1</sup> Both of these agents are CNS depressants. The doses employed in this study were relatively low. Higher doses would likely produce greater CNS suppression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jann MW, Hon YY, Shamsi SA, et al, “Lack of Pharmacokinetic Interaction Between Lamotrigine and Olanzapine in Healthy Volunteers,” <i>Pharmacother</i>, 2006, 26(5):627-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16637792\">[PubMed 16637792]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3945":"<p><b>Title</b> Warfarin / Tolterodine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tolterodine may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of warfarin if tolterodine is initiated, and decreased effects if tolterodine is discontinued.</p> \n<p><b>Discussion</b> Three case reports describe increased INR in warfarin-stable patients occurring within a couple of weeks of initiating tolterodine.<sup>1,2</sup> Discontinuation of tolterodine resulted in a decrease in INR. The pharmacokinetics of R-warfarin and S-warfarin (25 mg single dose) were unchanged in 20 normal subjects when administered following a 4-day course of tolterodine (2 mg twice daily).<sup>3</sup> And, the anticoagulant effects of warfarin appeared to be unaffected by tolterodine administration. A reason(s) for the observations described in the case reports is unclear. It is doubtful that displacement from protein binding sites, or alterations in/competition for cytochrome P450 enzymes, adequately explain these observations. The mechanism may simply be related to an increased sensitivity of some patients to decreased gastrintestinal transit caused by the anticholingergic agent, tolterodine, resulting in increased absorption of the anticoagulant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Colucci VJ and Rivey MP, “Tolterodine-Warfarin Drug Interaction,” <i>Ann Pharmacother</i>, 1999, 33(11):1173-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10573314\">[PubMed 10573314]</a></p>\n<p>2. Taylor JR, “Probable Interaction Between Tolterodine and Warfarin,” <i>Pharmacother</i>, 2006, 26(5):719-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16718947\">[PubMed 16718947]</a></p>\n<p>3. Rahimy M, Hallen B, and Narang P, “Effect of Tolterodine on the Anticoagulant Actions and Pharmacokinetics of Single-Dose Warfarin in Healthy Volunteers,” <i>Arzneimittelforschung</i>, 2002, 52(12):890-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12572529\">[PubMed 12572529]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3946":"<p><b>Title</b> Indinavir / Venlafaxine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Venlafaxine may decrease the serum concentration of Indinavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Caution should be employed when administering venlafaxine to a patient receiving “un-boosted” indinavir therapy. Reduced efficacy of indinavir seems possible.</p> \n<p><b>Discussion</b> The AUC of indinavir (800 mg single dose) was decreased 28% in 9 normal subjects when administered following a 10-day course of venlafaxine (50 mg three times daily).<sup>1</sup> The pharmacokinetics of venlafaxine were unaffected by indinavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levin GM, Nelson LA, DeVane CL, et al, “A Pharmacokinetic Drug-Drug Interaction Study of Venlafaxine and Indinavir,” <i>Psychopharmacol Bull</i>, 2001, 35(2):62-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12397887\">[PubMed 12397887]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3947":"<p><b>Title</b> Pioglitazone / Antifungal Agents (Azole Derivatives, Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pioglitazone. Applicable Isavuconazonium considerations are addressed in separate monographs. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antifungal Agents (Azole Derivatives, Systemic) Interacting Members</b> Fluconazole, Itraconazole*, Ketoconazole (Systemic), Posaconazole, Voriconazole<br><b>Exception</b> Isavuconazonium Sulfate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of pioglitazone was increased 34% in normal subjects when coadministered with ketoconazole (200 mg twice daily).<sup>1</sup> In another study itraconazole (100 mg twice daily) did not affect the pharmacokinetics of pioglitazone.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Actos [package insert]. Indianapolis, IN: Eli Lilly and Company, 2004.</p>\n<p>2. Jaakkola T, Backman JT, Neuvonen M, et al, “Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone,” <i>Clin Pharmacol Ther</i>, 2005, 77(5):404-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15900286\">[PubMed 15900286]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3948":"<p><b>Title</b> Thiazolidinediones / Leukotriene Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Leukotriene Receptor Antagonists do not appear to affect serum concentration of Thiazolidinediones. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Thiazolidinediones Interacting Members</b> Lobeglitazone, Pioglitazone*, Rosiglitazone</p>\n <p><b>Leukotriene Receptor Antagonists Interacting Members</b> Montelukast*, Pranlukast, Zafirlukast*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In vitro data demonstrate an ability of montelukast to inhibit the CYP2C8-mediated metabolism of rosiglitazone, a known 2C8 substrate.<sup>1</sup> However, the AUC of pioglitazone (15 mg) was essentially unchanged in 12 normal subjects when received following a 3-day course of either montelukast (10 mg daily) or zafirlukast (20 mg twice daily).<sup>2</sup> No data is available for rosiglitazone, but similar results are expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Walsky RL, Obach RS, Gaman EA, et al, “Selective Inhibition of Human Cytochrome P4502C8 by Montelukast,” <i>Drug Metab Dispos</i>, 2005, 33(3):413-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15608135\">[PubMed 15608135]</a></p>\n<p>2. Jaakkola T, Backman JT, Neuvonen M, et al, “Montelukast and Zafirlukast Do Not Affect the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone,” <i>Eur J Clin Pharmacol</i>, 2006, 62(7):503-9. [Epub ahead of print, May 3, 2006]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16670899\">[PubMed 16670899]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3949":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Voriconazole may decrease the metabolism of Estrogen Derivatives (Contraceptive). Estrogen Derivatives (Contraceptive) may increase the serum concentration of Voriconazole. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased side effects of estrogens and voriconzole during concomitant therapy.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol*, Mestranol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinyl estradiol (35 mcg daily as part of a combination oral contraceptive) was increased 61% in normal subjects when coadministered with voriconazole (400 mg every 12 hours on day 1, then 200 mg every 12 hours for 3 days).<sup>1</sup> The AUC of voriconazole was increased 46%. Voriconazole likely inhibited the CYP3A4-mediated metabolism of ethinyl estradiol. The mechanism of the observed increase in voriconazole is unclear. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vfend (voriconazole). New York, NY: Pfizer Inc, March 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3950":"<p><b>Title</b> Zidovudine / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may decrease the metabolism of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased side effects of zidovudine during concomitant use with fluconazole.</p> \n<p><b>Discussion</b> The AUC of zidovudine (200 mg every 8 hours) was increased 74% in 12 HIV-infected men when coadministered with fluconazole (400 mg daily) for 7 days.<sup>1</sup> Other data confirms the ability of fluconazole to inhibit the metabolism or increase the half-life of zidovudine.<sup>2,3</sup> Fluconazole may interfere with the uridine-5'-diphospho-glucuronosyltransferase (UGT)-mediated metabolism of zidovudine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sahai J, Gallicano K, Pakuts A, et al, “Effect of Fluconazole on Zidovudine Pharmacokinetics in Patients Infected with Human Immunodeficiency Virus,” <i>J Infect Dis</i>, 1994, 169(5):1103-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8169401\">[PubMed 8169401]</a></p>\n<p>2. Trapnell CB, Klecker RW, Jamis-Dow C, et al, “Glucuronidation of 3'-azido-3'-deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid,” <i>Antimicrob Agents Chemother</i>, 1998, 42(7):1592-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9660989\">[PubMed 9660989]</a></p>\n<p>3. Brockmeyer NH, Tillmann I, Mertins L, et al, “Pharmacokinetic Interaction of Fluconazole and Zidovudine in HIV-Positive Patients,” <i>Eur J Med Res</i>, 1997, 2(9):377-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9300934\">[PubMed 9300934]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3951":"<p><b>Title</b> Zidovudine / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methadone may increase the serum concentration of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for an increased risk of zidovudine-related side effects during concomitant use of methadone.</p> \n<p><b>Discussion</b> The AUC of zidovudine was increased 43% in 9 HIV-infected patients during concomitant administration of methadone.<sup>1</sup> A similar 8-patient study demonstrated increased zidovudine AUC (29% to 41%).<sup>2</sup> Methadone concentrations are not appreciably altered by zidovudine administration.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwartz EL, Brechbuhl AB, Kahl P, et al, “Pharmacokinetic Interactions of Zidovudine and Methadone in Intravenous Drug-Using Patients with HIV Infection,” <i>J Acquir Immune Defic Syndr</i>, 1992, 5(6):619-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1588496\">[PubMed 1588496]</a></p>\n<p>2. McCance-Katz EF, Rainey PM, Jatlow P, et al, “Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262),” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1998, 18(5):435-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9715839\">[PubMed 9715839]</a></p>\n<p>3. McCance-Katz EF, Rainey PM, Friedland G, et al, “Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition,” <i>Am J Addict</i>, 2001, 10(4):296-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11783744\">[PubMed 11783744]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3952":"<p><b>Title</b> Anastrozole / Tamoxifen</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tamoxifen may decrease the serum concentration of Anastrozole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Based on clinical and pharmacokinetic data, manufacturers recommend against the use of this combination of drug therapy.<sup>1,2</sup></p> \n<p><b>Discussion</b> Mean serum concentrations of anastrozole (1 mg daily) were decreased 27% in patients receiving concomitant tamoxifen (20 mg daily) in the ATAC trial.<sup>3</sup> In contrast, the concomitant administration of these agents does not appear to affect the pharmacokinetics of tamoxifen.<sup>4</sup> Clinical outcomes in the ATAC trial were not improved with combination therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nolvadex [package insert]. Wilmington, DE: AstraZeneca Pharmaceutical LP, 2003.</p>\n<p>2. Arimidex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.</p>\n<p>3. Dowsett M, Cuzick J, Howell A, et al, “Pharmacokinetics of Anastrozole and Tamoxifen Alone, and in Combination, During Adjuvant Endocrine Therapy for Early Breast Cancer in Postmenopausal Women: A Sub-Protocol of the 'Arimidex and Tamoxifen Alone or in Combination' (ATAC) Trial,” <i>Br J Cancer</i>, 2001, 85(3):317-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11487258\">[PubMed 11487258]</a></p>\n<p>4. Dowsett M, Tobias JS, Howell A, et al, “The Effect of Anastrozole on the Pharmacokinetics of Tamoxifen in Post-Menopausal Women with Early Breast Cancer,” <i>Br J Cancer</i>, 1999, 79:311-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9888474\">[PubMed 9888474]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3953":"<p><b>Title</b> Letrozole / Tamoxifen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tamoxifen may decrease the serum concentration of Letrozole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The clinical impact of the pharmacokinetic changes of letrozole during concomitant therapy are unclear. Sequential therapy appears safe and effective.</p> \n<p><b>Discussion</b> Serum concentrations of letrozole (2.5 mg daily) were decreased 38% in 12 female patients following 6 weeks of concomitant administration of tamoxifen (20 mg daily).<sup>1</sup> In contrast, serum concentrations of tamoxifen do not appear to be affected by letrozole.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dowsett M, Pfister C, Johnston SRD, et al, “Impact of Tamoxifen on the Pharmacokinetics and Endocrine Effects of the Aromatase Inhibitor Letrozole in Postmenopausal Women with Breast Cancer,” <i>Clin Cancer Res</i>, 1999, 5:2238-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10499602\">[PubMed 10499602]</a> </p>\n<p>2. Ingle JN, Suman VJ, Johnson PA, et al, “Evaluation of Tamoxifen Plus Letrozole with Assessment of Pharmacokinetic Interaction in Postmenopausal Women with Metastatic Breast Cancer,” <i>Clin Cancer Res</i>, 1999, 5:1642-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10430063\">[PubMed 10430063]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3954":"<p><b>Title</b> Sildenafil / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Sildenafil. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of sildenafil (50 mg) was increased 40% in 12 normal subjects when administered following an 10-day course of fluvoxamine (50 mg daily for 3 days, then 100 mg daily for 7 days).<sup>1</sup> The clinical significance of this interaction would appear limited. The successful use of sildenafil for the treatment of fluvoxamine-induced erectile dysfunction has been reported.<sup>2</sup> The mechanism of the pharmacokinetic effect is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hesse C, Siedler H, Burhenne J, et al, “Fluvoxamine Affects Sildenafil Kinetics and Dynamics,” <i>J Clin Psychopharmacol</i>, 2005, 25(6):589-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16282844\">[PubMed 16282844]</a></p>\n<p>2. Balon R, “Fluvoxamine-Induced Erectile Dysfunction Responding to Sildenafil,” <i>J Sex Marital Ther</i>, 1998, 24(4):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9805292\">[PubMed 9805292]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3955":"<p><b>Title</b> Repaglinide / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may decrease the metabolism of Repaglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of repaglinide (2 mg) was increased 19% in normal subjects when administered following the consumption of 300 mL of grapefruit juice.<sup>1</sup> No changes in blood glucose concentrations were noted. This modest pharmacokinetic effect is likely due to inhibition of intestinal CYP3A4 enzymes by grapefruit juice constituents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bidstrup TB, Damkier P, Olsen AK, et al, “The Impact of CYP2C8 Polymorphism and Grapefruit Juice on the Pharmacokinetics of Repaglinide,” <i>Br J Clin Pharmacol</i>, 2006, 61(1):49-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16390351\">[PubMed 16390351]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3956":"<p><b>Title</b> Warfarin / Mefloquine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mefloquine may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased INR and risk of bleeding during concomitant use of warfarin and mefloquine.</p> \n<p><b>Discussion</b> Two case reports describe markedly increased prothrombin times, and bleeding, in warfarin-stable patients following the initiation of mefloquine therapy.<sup>1</sup> The mechanism of this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Loefler I, “Mefloquine and Anticoagulant Interaction,” <i>J Travel Med</i>, 2003, 10(3):194-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12757697\">[PubMed 12757697]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3960":"<p><b>Title</b> ZOLMitriptan / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of ZOLMitriptan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of zolmitriptan when coadministred with cimetidine.</p> \n<p><b>Discussion</b> The manufacturer reports that the AUC of zolimitriptan (5 mg single dose) were approximately doubled when administered following a dose of cimetidine.<sup>1</sup> A mechanism for this observation is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zomig [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3962":"<p><b>Title</b> Mercaptopurine / AzaTHIOprine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of azathioprine and mercaptopurine should be avoided.</p> \n<p><b>Discussion</b> Azathioprine and mercaptopurine are commercially available products used for the treatment of different diseases. However, azathioprine is hepatically metabolized to mercaptopurine, and their combined use can thus result in mercaptopurine toxicity, namely in the form of profound myelosuppression. At least one fatality due to concomitant use of these drugs has been reported.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. ISMP Medication Safety Alert, Institute for Safe Medication Practices, Huntingdon Valley, PA, 2006, 11(13):2-3.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3963":"<p><b>Title</b> Warfarin / Mitotane</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mitotane may diminish the anticoagulant effect of Warfarin. Mitotane may decrease the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects when initiating mitotane. Warfarin dose increases may be necessary.</p> \n<p><b>Discussion</b> A single case report describes decreased effects of warfarin that eventually resolved, during concomitant therapy with mitotane.<br><br>Though a specific mechanism for this observation is not certain, mitotane is classified as a strong inducer of CYP3A,<sup>2,3</sup> so accelerated metabolism of the less potent R-warfarin enantiomer via CYP3A may be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cuddy PG, Loftus LS. Influence of mitotane on the hypoprothrombinemic effect of warfarin. <i>South Med J</i>. 1986;79(3):387-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3952554\">[PubMed 3952554]</a></p>\n<p>2. Prescribing information. Lysodren (mitotane). Princeton, NJ: Bristol-Myers Squibb Company, Novemeber 2013.</p>\n<p>3. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh Jd, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. <i>Eur J Endocrinol</i>. 2011;164(4):621-626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21220434\">[PubMed 21220434]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3964":"<p><b>Title</b> Repaglinide / Leukotriene Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Leukotriene Receptor Antagonists do not appear to affect serum concentration of Repaglinide. <b>Severity</b> N/A <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Leukotriene Receptor Antagonists Interacting Members</b> Montelukast, Pranlukast, Zafirlukast</p>\n</div> \n<p><b>Discussion</b> Montelukast (10 mg daily for 3 days) had no appreciable effect on the pharmacokinetics of repaglinide (0.25 mg single dose) in 12 normal subjects.<sup>1</sup> The same study demonstrated significant effects of telithromycin (800 mg daily for 3 days) on repaglinide. The effects of telithromycin were unaltered when montelukast was added to the 3 day, pre-repaglinide regimen. Although montelukast is noted to be a potent in vitro inhibitor of CYP2C8,<sup>2,3</sup> such does not appear to be of concern in vivo.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kajosaari LI, Niemi M, Backman JT, et al, “Telithromycin, but not Montelukast, Increases the Plasma Concentrations and Effects of the Cytochrome P450 3A4 and 2C8 Substrate Repaglinide,” <i>Clin Pharmacol Ther</i>, 2006, 79(3):231-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16513447\">[PubMed 16513447]</a></p>\n<p>2. Walsky RL, Obach RS, Gaman EA, et al, “Selective Inhibition of Human Cytochrome P4502C8 by Montelukast,” <i>Drug Metab Dispos</i>, 2005, 33(3):413-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15608135\">[PubMed 15608135]</a></p>\n<p>3. Walsky RL, Gaman EA, and Obach RS, “Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8,” <i>J Clin Pharmacol</i>, 2005, 45(1):68-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15601807\">[PubMed 15601807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3965":"<p><b>Title</b> Salicylates / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the anticoagulant effect of other Salicylates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased incidence of signs and symptoms of bleeding if multiple salicylates are used.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> The concomitant use of multiple salicylates would seem to increase the risk of adverse events, in particular those associated with reduced platelet aggregation.<sup>1,2</sup> Caution is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Salsalate [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; April 2008.</p>\n<p>2. Kaopectate (bismuth subsalicylate) [prescribing information]. Chattanooga, TN: Chatem Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3967":"<p><b>Title</b> Zaleplon / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may decrease the metabolism of Zaleplon. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The initial dose of zaleplon, in patients receiving cimetidine, should be 5 mg.<sup>1</sup></p> \n<p><b>Discussion</b> The AUC of zaleplon (10 mg) was increased 85% when concomitantly administered with cimetidine (800 mg).<sup>1</sup> Inhibition of aldehyde oxidase and CYP3A4 by cimetidine is the probable mechanism of this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sonata [package insert]. Bristol, TN: King Pharmaceuticals, Inc. 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3969":"<p><b>Title</b> Tetracyclines / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of tetracycline antibiotics and magnesium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In general, the coadministration of oral magnesium salts and oral tetracycline derivatives should be avoided. Interactions can be minimized by administering oral magnesium preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivatives. Monitor for decreased therapeutic effect of oral tetracycline derivatives.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> The oral bioavailability of tetracycline (250 mg) was decreased 90% when coadministered with aluminum-magnesium hydroxide get (30 mL).<sup>1</sup> In another study, magnesium aluminum silicate (the suspending agent in a bismuth-containing product) appeared to be responsible for decreasing the AUC of tetracycline by 27%.<sup>2</sup> Other data appears to support these observations.<sup>3</sup> Tetracycline derivatives likely bind to magnesium ions in the GI tract, forming a non-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Garty M and Hurwitz A, “Effect of Cimetidine and Antacids on Gastrointestinal Absorption of Tetracycline,” <i>Clin Pharmacol Ther</i>, 1980, 28(2):203-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7398187\">[PubMed 7398187]</a></p>\n<p>2. Healy DP, Dansereau RJ, Dunn AB, et al, “Reduced Tetracycline Bioavailability Caused by Magnesium Aluminum Silicate in Liquid Formulations of Bismuth Subsalicylate,” <i>Ann Pharmacother</i>, 1997, 31(12):1460-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9416381\">[PubMed 9416381]</a></p>\n<p>3. Khalil SA, Daabis NA, Naggar VF, et al, “Effect of Magnesium Trisilicate and Citric Acid on the Bioavailability of Tetracycline in Man,” <i>Pharmazie</i>, 1977, 32(8-9):519-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=201941\">[PubMed 201941]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3970":"<p><b>Title</b> Iron Salts / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of oral iron preparations in patients receiving proton pump inhibitors. This may be clinically evident and important in iron-deficient patients.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Two case reports demonstrate reduced efficacy of oral iron preparations in the treatment of iron-deficiency anemia when patients are also receiving omeprazole.<sup>1</sup> Increased gastrointestinal pH is associated with decreased iron absorption.<sup>2</sup> Additionally, stomach acidity appears to be required for releasing iron from dietary sources.<sup>3</sup> The overall impact on the state of iron-deficiency is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sharma VR, Brannon MR, and Carloss EA, “Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia,” <i>Southern Med J</i>, 2004, 97(9):887-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15455980\">[PubMed 15455980]</a></p>\n<p>2. Salovaara S, Sandberg A-S, and Andlid T, “Combined Impact of pH and Organic Acids on Iron Uptake by Caco-2 Cells,” <i>J Agric Food Chem</i>, 2003, 51:7820-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14664552\">[PubMed 14664552]</a></p>\n<p>3. Miret S, Simpson RJ, and McKie AT, “Physiology and Molecular Biology of Dietary Iron Absorption,” <i>Ann Rev Nutr</i>, 2003, 23:283-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12626689\">[PubMed 12626689]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3971":"<p><b>Title</b> Travelers' Diarrhea and Cholera Vaccine / Typhoid Vaccine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Typhoid Vaccine may diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Separate the dosing of encapsulated oral typhoid vaccine and the oral travelers' diarrhea and cholera vaccine by at least 8 hours.</p> \n<p><b>Discussion</b> The prescribing information for travelers' diarrhea and cholera vaccine recommends avoiding concomitant administration of encapsulated oral typhoid vaccine and to allow at least 8 hours between administration of these agents.<sup>1</sup> Concomitant administration of encapsulated oral typhoid vaccine and the oral travelers' diarrhea and cholera vaccine may result in diminished effects of one or both vaccines.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dukoral (travelers' diarrhea and cholera vaccine). Toronto, Ontario: Sanofi Pasteur Limited, October 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3972":"<p><b>Title</b> Salicylates / Nonsteroidal Anti-Inflammatory Agents (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant use of nonselective NSAIDs and salicylates. Ibuprofen, and possibly other nonselective NSAIDs, may reduce the cardioprotective effects of aspirin. It seems prudent to avoid regular, frequent use of ibuprofen in patients receiving aspirin for its cardioprotective effects. Alternative analgesics (e.g., acetaminophen) may be a safer choice. Patients may require counseling about the appropriate timing of ibuprofen and aspirin dosing. Ibuprofen should be administered 30-120 minutes after immediate release aspirin, 2 to 4 hours after extended release aspirin, or at least 8 hours before aspirin.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen*, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate*, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen*, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Sulindac*, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin*, Zaltoprofen</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal<br><b>Exception</b> Choline Magnesium Trisalicylate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The combination of a salicylate and an NSAID may increase the risk of gastrointestinal bleeding. Further, aspirin has been noted to decrease serum concentrations of a variety of nonsteroidal anti-inflammatory agents (NSAIDs), sometimes by more than 50% (e.g., flurbiprofen).<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> The interactions appear to be of minimal clinical significance. The mechanism(s) for these interactions are likely related to the potential for aspirin to displace the NSAID from plasma protein binding sites, thus increasing the potential for its elimination. The clinical effect of this interaction may be muted by the combined effect of a relative increase in free (unbound) NSAID, and the anti-inflammatory activity of aspirin.<br><br>Finally, some data suggest that ibuprofen and naproxen may limit the cardioprotective effect of aspirin (used for secondary prevention of cardiovascular events).<sup>13,14,15</sup> Other data suggest that the NSAID, alone, may provide cardioprotection, but does not enhance the protection provided by aspirin if coadministered.<sup>16</sup> Analysis of an electronic prescription database of patients with cardiovascular disease who were taking aspirin revealed a higher frequency of cardiovascular mortality in patients also taking ibuprofen.<sup>17</sup> A cohort study of 4,975 cases of acute myocardial infarction failed to demonstrate any clinically significant pharmacodynamic interaction between aspirin and NSAIDs on the risk of AMI.<sup>18</sup> Both agents are cyclo-oxygenase (COX) inhibitors. COX-1 catalyzes a process that eventually produces thromboxaneA<sub>2</sub>, a platelet agonist. Aspirin is an irreversible COX inhibitor, whereas ibuprofen (and other NSAIDs) are reversible inhibitors. It is surmised that ibuprofen may exhibit greater affinity than aspirin for the active site on the enzyme, or, if dosed regularly (or prior to aspirin) it would gain first access to the active site. In either case, aspirin inhibition of COX (irreversible) would be limited in favor of ibuprofen inhibition (reversible), thus affording reduced overall COX inhibition. Agents with greater preference for the COX-2 receptors (those associated with inflammation) would appear to be of less risk.<sup>19</sup> A definitive understanding of this purported interaction is lacking. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rubin A, Rodda BE, Warrick P, Gruber CM Jr, Ridolfo AS. Interactions of aspirin with nonsteroidal antiinflammatory drugs in man. <i>Arthritis Rheum</i>. 1973;16(5):635-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4582611\">[PubMed 4582611]</a></p>\n<p>2. Kaiser DG, Brooks CD, Lomen PL. Pharmacokinetics of flurbiprofen. <i>Am J Med</i>. 1986;80(3A):10-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3963013\">[PubMed 3963013]</a></p>\n<p>3. Brooks PM, Khong TK. Flurbiprofen-aspirin interaction: a double-blind crossover study. <i>Curr Med Res Opin</i>. 1977;5(1):53-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=71972\">[PubMed 71972]</a></p>\n<p>4. Grennan DM, Ferry DG, Ashworth ME, Kenny RE, Mackinnon M. The aspirin-ibuprofen interaction in rheumatoid arthritis. <i>Br J Clin Pharmacol</i>. 1979;8(5):497-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=389264\">[PubMed 389264]</a></p>\n<p>5. Jeremy R, Towson J. Interaction between aspirin and indomethacin in the treatment of rheumatoid arthritis. <i>Med J Aust</i>. 1970;2(3):127-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5455762\">[PubMed 5455762]</a></p>\n<p>6. Kwan KC, Breault GO, Davis RL, et al. Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. <i>J Pharmacokinet Biopharm</i>. 1978;6(6):451-476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=731412\">[PubMed 731412]</a></p>\n<p>7. Torgyan S, Wagner L, Neumann T, Pakuts B, Csanyi M. A comparative study with indomethacin and combined indomethacin sodium-salicylate in rheumatoid arthritis. <i>Int J Clin Pharmacol Biopharm</i>. 1979;17(11):439-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=389838\">[PubMed 389838]</a></p>\n<p>8. Alvan G, Ekstrand R. Clinical effects of indomethacin and additive clinical effect of indomethacin during salicylate maintenance therapy. <i>Scand J Rheumatol Suppl</i>. 1981;39:29-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6946553\">[PubMed 6946553]</a></p>\n<p>9. Williams RL, Upton RA, Buskin JN, Jones RM. Ketoprofen-aspirin interactions. <i>Clin Pharmacol Ther</i>. 1981;30(2):226-231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7249506\">[PubMed 7249506]</a></p>\n<p>10. Segre EJ, Chaplin M, Forchielli E, Runkel R, Sevelius H. Naproxen-aspirin interactions in man. <i>Clin Pharmacol Ther</i>. 1974;15(4):374-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4821440\">[PubMed 4821440]</a></p>\n<p>11. Hobbs DC, Twomey TM. Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. <i>J Clin Pharmacol</i>. 1979;19(5-6):270-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=89124\">[PubMed 89124]</a></p>\n<p>12. Cressman WA, Wortham GF, Plostnieks J. Absorption and excretion of tolemetin in man. <i>Clin Pharmacol Ther</i>. 1976;19(2):224-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1261159\">[PubMed 1261159]</a></p>\n<p>13. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet</i>. 2003;361(9357):573-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598144\">[PubMed 12598144]</a></p>\n<p>14. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. <i>N Engl J Med</i>. 2001;345(25):1809-1817. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11752357\">[PubMed 11752357]</a></p>\n<p>15. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>J Am Coll Cardiol</i>. 2005;45(8):1295-1301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15837265\">[PubMed 15837265]</a></p>\n<p>16. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. <i>J Am Coll Cardiol</i>. 2004;43(6):985-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15028354\">[PubMed 15028354]</a></p>\n<p>17. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet</i>. 2003;361(9357):573-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598144\">[PubMed 12598144]</a></p>\n<p>18. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. <i>Circulation</i>. 2004;109(24):3000-3006. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197149\">[PubMed 15197149]</a></p>\n<p>19. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. <i>Lancet</i>. 2003;361(9357):542-544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598136\">[PubMed 12598136]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3973":"<p><b>Title</b> Iron Salts / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of oral iron preparations in patients receiving H2 antagonists. This may be clinically evident and important in iron-deficient patients.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n <p><b>Iron Salts Interacting Members</b> Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> Two case reports demonstrate reduced efficacy of oral iron preparations in the treatment of iron-deficiency anemia when patients are also receiving omeprazole.<sup>1</sup> Increased gastrointestinal pH is associated with decreased iron absorption.<sup>2</sup> Additionally, stomach acidity appears to be required for releasing iron from dietary sources.<sup>3</sup> The overall impact on the state of iron-deficiency is unclear. Similar results might be expected with the use of H2 antagonists.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sharma VR, Brannon MR, and Carloss EA, “Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia,” <i>Southern Med J</i>, 2004, 97(9):887-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15455980\">[PubMed 15455980]</a></p>\n<p>2. Salovaara S, Sandberg A-S, and Andlid T, “Combined Impact of pH and Organic Acids on Iron Uptake by Caco-2 Cells,” <i>J Agric Food Chem</i>, 2003, 51:7820-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14664552\">[PubMed 14664552]</a></p>\n<p>3. Miret S, Simpson RJ, and McKie AT, “Physiology and Molecular Biology of Dietary Iron Absorption,” <i>Ann Rev Nutr</i>, 2003, 23:283-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12626689\">[PubMed 12626689]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3974":"<p><b>Title</b> Quinolones / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the increased risk of seizure that may accompany the concomitant use of NSAIDs and quinolone antibiotics. Additional factors that may be associated with an increased risk of such an interaction include: renal dysfunction, history of seizure or other neurological disorder, and high doses/serum concentrations of either agent.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> Several case reports suggest an increased risk of seizures in patients receiving concomitant NSAIDs and quinolone antibiotics.<sup>1,2,3,4</sup> In contrast, an epidemiologic study of 856 patients treated with a variety of NSAIDs and quinolone antibiotics failed to identify any seizure activity.<sup>5</sup><br><br>In vitro and animal data describe enhanced central GABA-A inhibition as a plausible mechanism of such an interaction.<sup>6,7,8,9,10</sup> However, other in vitro studies have found that only some, but not all, NSAIDs potentiate the epileptogenic potential of the quinolones,<sup>11</sup> and that NSAIDs do not increase the GABA inhibition of quinolones.<sup>12</sup> It is also known that quinolone antibiotics pose a risk of inducing seizures in susceptible individuals (a risk that may be increased in patients with renal failure, previous history of seizures or other neurological disorders). Of note, one controlled study found that concurrent use of diclofenac was associated with an average 58% increase in ciprofloxacin maximum serum concentrations (Cmax), increased AUC, and decreased time to maximum concentration (i.e., more rapid drug absorption) in a study of 12 volunteers.<sup>13</sup> Considering the purported epileptogenic potential of ciprofloxacin and other quinolones, this study raises one possible explanation for the published case reports suggesting a higher seizure risk with such combinations.<br><br>Overall, given the limited number of reports of an interaction relative to the volume of use of these products, the risk of this possible interaction appears low, except in the presence of additional risk factors (e.g., renal dysfunction, history of seizure or other neurological disorder, high doses/serum concentrations of either agent).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bomford J, “Ciprofloxacin,” <i>Pharm J</i>, 1995, 255:674.</p>\n<p>2. Takeo G, Shibuya N, Motomura M, et al, “A New DNA Gyrase Inhibitor induces Convulsions: A Case Report and Animal Experiments,” <i>Chemotherapy (Tokyo)</i>, 1989, 37:1154-59.</p>\n<p>3. Morita H, Maemura K, Sakai Y, et al, “A Case with Convulsions, Loss of Consciousness and Subsequent Acute Renal Failure Caused by Enoxacin and Fenbufen,” <i>Nippon Naika Gakkai Zasshi</i>, 1988, 77:744-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3216153\">[PubMed 3216153]</a> </p>\n<p>4. Mizuno J, Takumi Z, Kaneko A, et al, “Convulsion Following the Combination of Single Preoperative Oral Administration of Enoxacin and Single Postoperative Intravenous Administration of Flurbiprofen Axetil,” <i>Jpn J Anethesiol</i>, 2001, 50:425-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11345761\">[PubMed 11345761]</a></p>\n<p>5. Mannino S, Garcia-Rodriguez LA, and Jick SS, “NSAIDs, Quinolones and Convulsions: An Epidemiologic Approach,” <i>Post Marketing Surveillance</i>, 1992, 6:119-28.</p>\n<p>6. Imanishi T, Akahane K, and Akaike N, “Evidence that a Hybrid Molecule of Norfloxacin and Biphenylacetic Acid is a Potent Antagonist at the GABAA Receptor,” <i>Neuropharmacology</i>, 1996, 35(9-10):1271-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9014142\">[PubMed 9014142]</a></p>\n<p>7. Tsutomi Y, Matsubayashi K, and Akahane K, “Quantitation of GABAA Receptor Inhibition Required for Quinolone-Induced Convulsions in Mice,” <i>J Antimicrob Chemother</i>, 1994, 34(5):737-46. [PubMed7706169 ]</p>\n<p>8. Motomura M, Kataoka Y, Takeo G, et al, “Hippocampus and Frontal Cortex are the Potential Mediatory Sites for Convulsions Induced by New Quinolones and Non-Steroidal Anti-Inflammatory Drugs,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1991, 29(6):223-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1651287\">[PubMed 1651287]</a></p>\n<p>9. Hori S, Kizu J, and Kawamura M, “Effects of Anti-Inflammatory Drugs on Convulsant Activity of Quinolones: A Comparative Study of Drug Interaction Between Quinolones and Anti-Inflammatory Drugs,” <i>J Infect Chemother</i>, 2003, 9:314-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14691652\">[PubMed 14691652]</a></p>\n<p>10. Shrivastava MP, Makde SD, Paranjpe BD, “Interaction of Ciprofloxacin with Diclofenac and Paracetamol in Relation to It's Epileptogenic Effect,” <i>Indian J Physiol Pharmacol</i>, 1997, 41(2):164-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9142563\">[PubMed 9142563]</a></p>\n<p>11. Squires RF, Saederup E, “Indomethacin/Ibuprofen-like Anti-inflammatory Agents Selectively Potentiate the Gamma-Aminobutyric Acid-Antagonistic Effects of Several Norfloxacin-like Quinolone Antibacterial Agents on [35S]t-butylbicyclophosphorothionate Binding,” <i>Mol Pharmacol</i>, 1993, 43(5):795-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8388990\">[PubMed 8388990]</a></p>\n<p>12. Segev S, Rehavi M, Rubinstein E, “Quinolones, Theophylline, and Diclofenac Interactions with the Gamma-Aminobutyric Acid Receptor,” <i>Antimicrob Agents Chemother</i>, 1988, 32(11):1624-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2855295\">[PubMed 2855295]</a></p>\n<p>13. Iqbal Z, Khan A, Naz A, et al, “Pharmacokinetic Interaction of Ciprofloxacin with Diclofenac: a Single-Dose, Two-Period Crossover Study in Healthy Adult Volunteers,” <i>Clin Drug Investig</i>, 2009, 29(4):275-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19301941\">[PubMed 19301941]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3975":"<p><b>Title</b> RaNITIdine / Propantheline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propantheline may increase the serum concentration of RaNITIdine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The bioavailability of oral ranitidine (150 mg) was increased 22% in 12 normal subjects when administered following a single dose of propantheline (15 mg).<sup>1</sup> This change would not be expected to be clinically significant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Donn KH, Eshelman FN, Plachetka JR, et al, “The Effects of Antacid and Propantheline on the Absorption of Oral Ranitidine,” <i>Pharmacotherapy</i>, 1984, 4(2):89-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6326064\">[PubMed 6326064]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3976":"<p><b>Title</b> Triazolam / RaNITIdine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RaNITIdine may increase the serum concentration of Triazolam. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of triazolam (0.25 mg) was increased approximately 28% in 30 subjects (ages 19-78) when administered following a 3-day course of ranitidine (150 mg twice daily).<sup>1</sup> The increase was only 10% in 19-60 year old subjects when 75 mg doses of ranitidine were used. However, in 61-78 year old subjects (n=12) the increase associated with 75 mg doses of ranitidine was 31%. Another study supports these findings, and confirm that ranitidine has no effect on intravenously administered triazolam.<sup>2</sup> The mechanism of these observations is unclear, although they are likely related to increased gastrointestinal pH offering a more favorable environment for the acid-labile triazolam. Elderly may be more sensitive to these effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. O'Conner-Semmes RL, Kersey K, Williams DH, et al, “Effect of Ranitidine on the Pharmacokinetics of Triazolam and Alpha-hydroxytriazolam in Both Young (19-60 years) and Older (61-78 years) People,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):126-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503006\">[PubMed 11503006]</a></p>\n<p>2. Vanderveen RP, Jirak JL, Peters GR, et al, “Effect on Ranitidine on the Disposition of Orally and Intravenously Administered Triazolam,” <i>Clin Pharm</i>, 1991, 10(7):539-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1860302\">[PubMed 1860302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3978":"<p><b>Title</b> Delavirdine / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifamycin Derivatives may increase the metabolism of Delavirdine. Delavirdine may increase the serum concentration of Rifamycin Derivatives. Specifically, Rifabutin serum concentration may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid coadministration of delavirdine with rifampin or rifabutin. Specific data and recommendations for use with rifapentine are not available. The effects of delavirdine are expected to be significantly reduced. The risk of toxicity of coadministered rifabutin is also expected to increase.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin*, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of delavirdine (400 mg every 8 hours) was decreased 97% in 7 patients when coadministered with rifampin (600 mg daily) for 15 days.<sup>1</sup> A similar study on the effects of rifabutin (300 mg daily) described an 84% decrease in delavirdine AUC during concomitant administration.<sup>2</sup> Additionally, an evaluation of the effect of delavirdine on the pharmacokinetics of rifabutin found an approximate 230% increase in rifabutin AUC.<sup>3</sup> The suspected mechanisms of these interactions are rifamycin induction of CYP3A4-mediated delavirdine metabolism and delavirdine inhibition of CYP3A4-mediated rifabutin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. <i>Clin Pharmacol Ther</i>. 1997;61(5):544-553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9164416\">[PubMed 9164416]</a></p>\n<p>2. Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. <i>Antiviral Res</i>. 1997;35(1):53-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9224961\">[PubMed 9224961]</a></p>\n<p>3. <i>Rescriptor</i> (delavirdine) [prescribing information]. Research Triangle Park, NC: Viiv Healthcare; August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3980":"<p><b>Title</b> Bleomycin / Gemcitabine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity.</p> \n<p><b>Discussion</b> Severe pulmonary toxicity (primarily pneumonitis) developed in 8 of 27 patients receiving gemcitabine as part of a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BAGCOPP).<sup>1</sup> The study (evaluating the use of this drug combination in the treatment of Hodgkin's Disease) was prematurely halted due to these events. It is presumed that the combination of gemcitabine and bleomycin were the likely cause of the increased incidence of pulmonary toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bredenfeld H, Franklin J, Nogova L, et al, “Severe Pulmonary Toxicity in Patients with Advanced-Stage Hodgkin's Disease Treated with a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group,” <i>J Clin Oncol</i>, 2004, 22(12):2424-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15136597\">[PubMed 15136597]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3981":"<p><b>Title</b> Gold Sodium Thiomalate / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of nitritoid reactions (facial flushing, nausea, vomiting, hypotension, syncope) during concomitant use of gold sodium thiomalate and ACEI. These symptoms would be expected to occur shortly after administration of the gold compound in patients who are already receiving an ACEI.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the development of “nitritoid” reactions (symptoms including facial flushing, nausea, vomiting, hypotension, syncope) during concomitant use of an angiotensin-converting enzyme inhibitor (ACEI), seemingly indicating the conveyance of an increased risk of this gold-associated adverse effect.<sup>1,2</sup> Reactions typically develop quickly (within minutes of gold administration) and are transient. The reason for an apparent increase in risk of developing these reactions during ACEI therapy is unclear. The vasodilatory effects of ACEI (due to their inhibition of bradykinin metabolism) may simply augment (and/or trigger) the cascade of symptoms.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nixon J and Pande I, “Gold, Nitritoid Reactions and Angiotensin-Converting Enzyme Inhibitors,” <i>Rheumatology (Oxford)</i>, 2006, 45(1):118-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16319093\">[PubMed 16319093]</a></p>\n<p>2. Netherlands Pharmacovigilence Center Lareb, “Sodium Aurothiomalate and Nitritoid Reactions:Concomitant Use of an ACE-Inhibitor as a Contributing Factor,” Accessed at http://www.lareb.nl/bijwerkingen/zoekresultaten.asp on December 20, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3983":"<p><b>Title</b> Estramustine / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the absorption of Estramustine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil<br><b>Exception</b> Calcium Chloride</p>\n</div> \n<p><b>Discussion</b> In a randomized, three-way, cross-over study in 6 patients treated for prostate cancer, estramustine phosphate was co-administered as a single dose (equivalent to 140 mg) with low calcium water, low calcium food, or milk.<sup>1</sup> The AUC of the estromustine metabolite was reduced by 33% and 59% when taken with food and milk, respectively. Similar results were reported for the estrone metabolite. The reduced absorption of estramustine is suspected to result from the formation of insoluble calcium complexes, which has been suggested based on <i>in vitro</i> data. The manufacturer of estramustine recommends that the drug be given on an empty stomach.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gunnarsson PO, Davidson T, Andersson SB, et al, “Impairment of Estramustine Phosphate Absorption by Concurrent Intake of Milk and Food,” <i>Eur J Clin Pharmacol</i>, 1990, 38(2):189-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338118\">[PubMed 2338118]</a></p>\n<p>2. Emcyt [package insert]. Kalamazoo, MI: Pharmacia and Upjohn Company, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3984":"<p><b>Title</b> Alteplase / Nitroglycerin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nitroglycerin may decrease the serum concentration of Alteplase. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concomitant use of intravenous nitroglycerin and alteplase may lead to a reduction in the thrombolytic effects of alteplase. Use the lowest dose of nitroglycerin possible. Closely monitor patient for evidence of adequate reperfusion and monitor for signs of reocclusion.</p> \n<p><b>Discussion</b> In the first human study to investigate this potential interaction, patients presenting with an acute myocardial infarction (AMI) received either tissue-type plasminogen activator (t-PA) plus nitroglycerin (n=36) or t-PA plus saline (n=11).<sup>1</sup> The t-PA dose was 100 mg infused over 3 hours, and all patients also received aspirin 165 mg on admission and heparin administerd following t-PA. Stable reperfusion was achieved in 91% of those receiving t-PA plus saline and in 44% of those receiving t-PA plus nitroglycerin (p&lt;0.02). Plasma concentrations of t-PA antigen were also statistically significantly lower in those receiving t-PA plus nitroglycerin for up to 6 hours after t-PA administration. In another study, anterior AMI patients (n=60) were randomly assigned to receive IV alteplase alone (n=33) or alteplase with concurrent IV nitroglycerin (n=27).<sup>2</sup> Both groups received a 3-hour alteplase infusion (10 mg bolus, followed by 40 mg over the first hour and 50 mg over the following two hours). Nitroglycerin was administered as a 100 mcg/min infusion over 8 hours. Both treatment groups were equally matched with respect to baseline demographics, cardiovascular risk factors, infarct size, and time to onset of thrombolytic therapy. Seventy-six percent of patients receiving alteplase alone showed evidence of reperfusion compared to 56% of patients receiving concomitant therapy. Alteplase therapy alone was also associated with a significant reduction in reperfusion time (19.6 minutes vs. 37.8 minutes), reocclusion rate (24% vs 53%), and nearly 3-fold higher peak plasma levels of t-PA antigen. Though a follow-up letter questioned the statistical analysis employed (and statistical significance of reported differences and statistical power),<sup>3</sup> the magnitude and direction of these differences do provide support (albeit not conclusive) for the existence of an interaction. The clinical significance of this interaction is unknown, despite the evidence of some negative pharmacodynamic consequences of the interaction, as large landmark trials demonstrating the efficacy of alteplase in AMI have generally allowed IV nitroglycerin use (eg, 77% of patients in GUSTO I received nitroglycerin<sup>4</sup>).<br><br>This phenomenon has not been reported with other thrombolytic agents.<br><br>Two independent mechanisms for the loss of thrombolytic effects have been proposed. Based on the known vasodilatory actions of nitroglycerin, increased hepatic blood flow may increase the rate of alteplase clearance from the systemic circulation. Alternatively, enhanced degradation of alteplase in human plasma in the presence of nitroglycerin has been shown <i>in vitro</i> by one investigator,<sup>5</sup> although previous data have shown alteplase (1 mg/mL) to be compatible with nitroglycerin (0.8 mg/mL) in saline.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nicolini FA, Ferrini D, Ottani F, et al, “Concurrent Nitroglycerin Therapy Impairs Tissue-Type Plasminogen Activator-Induced Thrombolysis in Patients with Acute Myocardial Infarction,” <i>Am J Cardiol</i>, 1994, 74(7):662-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7942523\">[PubMed 7942523]</a></p>\n<p>2. Romeo F, Rosano GMC, Martuscelli E, et al, “Concurrent Nitroglycerin Administration Reduces the Efficacy of Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Anterior Wall Myocardial Infarction,” <i>Am Heart J</i>, 1995, 130:692-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7572574\">[PubMed 7572574]</a></p>\n<p>3. Massel D, “Concomitant Nitroglycerin and rTPA,” <i>Am Heart J</i>, 1997, 133:713-4 [letter]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9200401\">[PubMed 9200401]</a></p>\n<p>4. Anon. “An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. The GUSTO Investigators,” <i>N Engl J Med</i>, 1993, 329(10):873-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8204123\">[PubMed 8204123]</a> </p>\n<p>5. White CM, Fan C, Chen BP, et al, “Assessment of the Drug Interaction between Alteplase and Nitroglycerin: an In Vitro Study,” <i>Pharmacotherapy</i>, 2000, 20(4):380-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10772366\">[PubMed 10772366]</a></p>\n<p>6. Lam XM, Ward CA, du Mee CP, “Stability and Activity of Alteplase with Injectable Drugs Commonly Used in Cardiac Therapy,” <i>Am J Health Syst Pharm</i>, 1995, 52(17):1904-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8528854\">[PubMed 8528854]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3985":"<p><b>Title</b> Paliperidone / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Paliperidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor response to paliperidone closely when starting carbamazepine, as an increase of paliperidone dose may be required. Similarly, monitor paliperidone therapy closely with any subsequent change to carbamazepine therapy (dose increases/decrease or discontinuation), as paliperidone dose may require further adjustment.</p> \n<p><b>Discussion</b> The AUC and maximum serum concentration (Cmax) of paliperidone were each reduced by an average of 37% following initiation of carbamazepine in an open-label study of 64 patients who received paliperidone extended-release (ER) 6 mg once daily for 7 days followed by paliperidone ER 6 mg once daily concomitantly with carbamazepine CR 200 mg twice daily for the subsequent 21 days.<sup>1</sup> Similarly, paliperidone concentrations were 44% to 66% lower with concurrent carbamazepine in other studies,<sup>2,3</sup> an effect that was shown to be dose-dependent in one study of 6 individuals where paliperidone concentrations were 44% lower with carbamazepine 200 mg/day, 64% lower with carbamazepine 400 mg/day, and 66% lower with carbamazepine 600 mg/day.<sup>3</sup> Other studies of the risperidone-carbamazepine interaction have similarly noted significant decreases in paliperidone (i.e., 9-OH-risperidone, which is an active metabolite of risperidone) concentrations with carbamazepine.<sup>4,5</sup><br><br>The mechanism of this interaction is uncertain. Paliperidone does not undergo substantial metabolism.<sup>6</sup> One study noted that concurrent carbamazepine only minimally decreased the amount of unchanged paliperidone excreted in the urine and increased the renal clearance of paliperidone by 35%, both suggesting a predominantly non-metabolism-related mechanism.<sup>1</sup> This increase in paliperidone renal clearance, together with evidence that paliperidone is transported by p-glycoprotein,<sup>7,8</sup> and that carbamazepine may upregulate p-glycoprotein expression in renal tubular cells,<sup>9</sup> suggests that enhanced p-glycoprotein-mediated efflux (i.e., increased renal elimination, decreased absorption, etc.) may be at least partially responsible for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch-Herben V, Cleton A, Berwaerts J, Vandebosch A, Remmerie B. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. <i>Clinical Pharm in Drug Dev</i>. 2014; (Epub ahead of print). doi: 10.1002/cpdd.122</p>\n<p>2. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: Its relationship with CYP2D6 genotypes. <i>Psychopharmacology (Berl)</i>. 2002;162(1):50-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12107617\">[PubMed 12107617]</a></p>\n<p>3. Yasui-Furukori N, Kubo K, Ishioka M, Tsuchimine S, Inoue Y. Interaction between paliperidone and carbamazepine. <i>Ther Drug Monit</i>. 2013;35(5):649-652. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24052066\">[PubMed 24052066]</a></p>\n<p>4. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. <i>J Pharmacokinet Pharmacodyn</i>. 2007;34(2):183-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136449\">[PubMed 17136449]</a></p>\n<p>5. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate. <i>Ther Drug Monit</i>. 2000;22(4):481-485. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10942191\">[PubMed 10942191]</a></p>\n<p>6. <i>Invega</i> (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.</p>\n<p>7. Suzuki Y, Tsuneyama N, Fukui N, et al. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia. <i>J Clin Psychopharmacol</i>. 2013;33(3):411-424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23609388\">[PubMed 23609388]</a></p>\n<p>8. Gunes A, Spina E, Dahl ML, Scordo MG. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. <i>Ther Drug Monit</i>. 2008;30(5):628-633. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18708991\">[PubMed 18708991]</a></p>\n<p>9. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. <i>Clin Pharmacol Ther</i>. 2004;76(3):192-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15371980\">[PubMed 15371980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3986":"<p><b>Title</b> Paliperidone / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Itraconazole may enhance the QTc-prolonging effect of Paliperidone. Itraconazole may decrease the metabolism of Paliperidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Itraconazole may increase the serum levels of paliperidone, presumably through inhibition of CYP3A4. Although the manufacturer of paliperidone suggests that cytochrome-mediated clearance is minimal,<sup>1</sup> it would seem prudent to avoid this combination if possible. If concomitant therapy is desired, closely monitor for increased paliperidone-related toxicity.</p> \n<p><b>Discussion</b> Nineteen schizophrenic patients stabilized on risperidone therapy (2-8 mg/day) for at least 2 months received itraconazole (200 mg/day) for 1 week.<sup>2</sup> Blood samples were taken prior to initiation of itraconazole, during concomitant therapy, and following 1 week after discontinuation of itraconazole. Plasma concentrations of both risperidone and 9-hydroxyrisperidone (paliperidone) were significantly elevated 1.7- and 1.6-fold, respectively, during concurrent itraconazole treatment, but returned to baseline after discontinuation of itraconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invega [package insert]. Mountain View, CA: ALZA Corporation, 2006.</p>\n<p>2. Jung SM, Kim K-A, Cho H-K, et al, “Cytochrome P450 3A Inhibitor Itraconazole Affects Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients,” <i>Clin Pharmacol Ther</i>, 2005, 78(5):520-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16321618\">[PubMed 16321618]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3988":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Sirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sirolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that an increased risk of angioedema has been reported with this combination. Caution patients regarding this increased risk, and urge them to immediately report any signs or symptoms suggestive of possible angioedema.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril*, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe a handful of patients developing edema in and around the facial region after initiation of angiotensin-converting enzyme therapy with existing stable sirolimus treatment. In one study of 52 renal transplant patients, 5 patients developed tongue edema within 1 month of starting rampiril (5 mg/day).<sup>1</sup> The patients had no history of allergic reaction, and the episodes were unremarkable for changes in eosinophil, IgE or Clq inhibitor levels. Symptoms resolved 2 weeks after discontinuing ramipril, without adjustment of sirolimus therapy. Ramipril was re-introduced 3 months later without incident at a lower dose. Another report documents 2 cases of non-pitting edema of the face occurring within 9 days of initiating enalapril (2.5 mg/day) or ramipril with ongoing sirolimus therapy in renal transplant recipients.<sup>2</sup> In the former case, facial, neck and upper thoracic edema was accompanied by urticarial erythematous skin lesions. Corticosteroid treatment and discontinuation of enalapril resulted in prompt resolution of symptoms. In the latter case, edema presented in a left, unilateral fashion involving the cheek, eyelid, and lips, accompanied by respiratory distress. Discontinuation of both sirolimus and ramipril resulted in symptom improvement. Of note, sirolimus was re-initiated in this patient without incident. <br><br>In one retrospecitive analysis, of 137 patients receiving an mTOR inhibitor and an ACE inhibitor, 6.6% developed angioedema (3.8 per 100 treatment-years) as compared to only 1.2% (0.5/100 treatment-years) of those receiving an mTOR inhibitor without an ACE inhibitor (n=172, including 119 on an angiotensin receptor blocker) and 2.1% (0.8/100 treatment-years) of those receiving mycophenolate plus an ACE inhibitor (n=462).<sup>3</sup> These figures also exceed the general rate of angioedema associated with ACE inhibitor use (independent of immunosuppressant use) in a recent study of a VA population, in which 0.2% of patients started on an ACE inhibitor experienced angioedema (0.197/100 patient-years).<sup>4</sup><br><br>The prescribing information for both sirolimus and everolimus (mTOR inhibitors) caution that angioedema has been reported with their use and that concurrent use with other drugs that are associated with development of angioedema, such as the ACE inhibitors, may increase the risk.<sup>5,6</sup><br><br>The specific mechanism by which the mTOR inhibitors increase the risk of angioedema is unclear. ACE inhibitors are thought to contribute to the development of angioedema through their ability to inhibit the metabolism of specific vasoactive kinins (e.g., bradykinin).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stallone G, Infante B, Di Paolo S, et al, “Sirolimus and Angiotensin-Converting Enzyme Inhibitors Together Induce Tongue Oedema in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2004, 19(11):2906-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15496567\">[PubMed 15496567]</a></p>\n<p>2. Burdese M, Rossetti M, Guarena C, et al, “Sirolimus and ACE-Inhibitors: A Note of Caution,” <i>Transplantation</i>, 2005, 79(2):251-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15665781\">[PubMed 15665781]</a></p>\n<p>3. Duerr M, Glander P, Diekmann F, et al, “Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant Recipients,” <i>Clin J Am Soc Nephrol</i>, 2010, 5(4):703-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20093343\">[PubMed 20093343]</a></p>\n<p>4. Miller DR, Oliveria SA, Berlowitz DR, et al, “Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors,” <i>Hypertension</i>, 2008, 51(6):1624-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18413488\">[PubMed 18413488]</a></p>\n<p>5. Prescribing information. Zortress (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 03/2010.</p>\n<p>6. Prescribing information. Rapamune (sirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3989":"<p><b>Title</b> Vitamin K Antagonists / Vorinostat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vorinostat may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased anticoagulant effects; closely monitor PT and INR when vorinostat treatment is initiated with ongoing coumarin derivative therapy.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The manufacturer of vorinostat notes a prolongation of the PT and increased INR in patients receiving concomitant coumarin derivatives.<sup>1</sup> The mechanism of this increased anticoagulant effect is unknown, but may be related to general thrombocytopenia induced by the antineoplastic agent. Close monitoring of the patient, with frequent assessment of PT/INR is recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zolinza [package insert]. Whitehouse Station, NJ: Merck &amp; Co, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3991":"<p><b>Title</b> Dasatinib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of dasatinib recommends that antacids should be administered 2 hours before, or 2 hours after, dasatinib in order to avoid an interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a study of 24 healthy volunteers, coadministration of a single 50 mg dose of dasatinib with 30 mL of aluminum hydroxide/magnesium hydroxide resulted in a 55% reduction in dasatinib AUC.<sup>1</sup> In these same subjects, giving the antacid 2 hours prior to dasatinib resulted in no AUC change, and a small increase in Cmax. The manufacturer suggests that reduced absorption is based on pH-dependent solubility. This mechanism is supported by similar reductions of dasatinib AUC in the presence of H2 antagonists and proton pump inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3992":"<p><b>Title</b> Dasatinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer of dasatinib recommends against the use of concomitant proton pump inhibitors due to significantly reduced absorption of dasatinib. Antacids (taken 2 hours before or after dasatinib administration) should be used in place of these agents if some acid-reducing therapy is needed.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The dasatinib dose-adjusted AUC was 58% lower among patients who received an acid suppressant compared to those who did not in a study of 18 patients with leukemia who were treated with dasatinib and either 30 mg lansoprazole (5 patients 12 courses), 20 mg or 40 mg of famotidine (4 patients, 5 courses), or no acid suppressant (6 patients, 14 courses).<sup>1</sup> According to the dasatinib prescribing information, administration of a single dose of dasatinib (100 mg) 22 hours after an omeprazole dose (40 mg/day) at steady state reduced the dasatinib AUC by 43% in a study of 14 healthy volunteers).<sup>2</sup> Similarly, the dasatinib AUC was reduced by an average of 78% with concurrent rabeprazole 20 mg twice daily in a study of 10 healthy volunteers.<sup>3</sup> A case report also describes a 16-year-old male who experienced a 32% decrease in dasatinib AUC with concurrent esomeprazole (40 mg/day) treatment.<sup>4</sup><br><br>Considering the longer-term acid suppression achieved with proton pump inhibitor or H2-antagonist therapy, the dasatinib manufacturer suggests the use of antacids (with 2-hour dose separation).<sup>2</sup><br><br>The likely mechanism for this apparent interaction is impaired absorption of dasatinib, which does appear to display pH-sensitive solubility,<sup>2</sup> due to the increase in gastric pH caused by a proton pump inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. <i>Cancer Chemother Pharmacol</i>. 2012;69(4):999-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22147077\">[PubMed 22147077]</a></p>\n<p>2. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016.</p>\n<p>3. Yago MR, Frymoyer A, Benet LZ, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. <i>AAPS J</i>. 2014;16(6):1358-1365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25274610\">[PubMed 25274610]</a></p>\n<p>4. Pape E, Michel D, Scala-Bertola J, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. <i>Br J Clin Pharmacol</i>. 2016;81(6):1195-1196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26833554\">[PubMed 26833554]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3993":"<p><b>Title</b> Dasatinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The manufacturer of dasatinib recommends against the use of concomitant H2-receptor antagonists due to significantly reduced absorption of dasatinib. Antacids (taken 2 hours before or after dasatinib administration) should be used in place of these agents if some acid-reducing therapy is needed.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The dasatinib dose-adjusted AUC was 58% lower among patients who received an acid suppressant compared to those who did not in a study of 18 patients with leukemia who were treated with dasatinib and either 30 mg lansoprazole (5 patients 12 courses), 20 mg or 40 mg of famotidine (4 patients, 5 courses), or no acid suppressant (6 patients, 14 courses).<sup>1</sup> Consistent with these findings, administration of a single 50 mg dose of dasatinib 10 hours after famotidine 40 mg resulted in an average 61% reduction in dasatinib AUC.<sup>2,3</sup> Additionally, a 3.6-fold increase in dasatinib AUC was observed after discontinuation of famotidine (20 mg daily) in a 79-year-old woman taking dasatinib (70 mg twice daily) for leukemia.<sup>4</sup> Given the longer-term acid suppression achieved with H2-antagonist or proton pump inhibitor therapy, the manufacturer suggests the use of antacids (with 2-hour dose separation).<sup>2</sup><br><br>The likely mechanism for this apparent interaction is impaired absorption of dasatinib, which does appear to display pH-sensitive solubility,<sup>2</sup> due to the increase in gastric pH caused by a H2-receptor antagonist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. <i>Cancer Chemother Pharmacol</i>. 2012;69(4):999-1004. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22147077\">[PubMed 22147077]</a></p>\n<p>2. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; September 2016.</p>\n<p>3. Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. <i>J Clin Pharmacol</i>. 2009;49(6):700-709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19395585\">[PubMed 19395585]</a></p>\n<p>4. Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. <i>Cancer Chemother Pharmacol</i>. 2012;70(2):351-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22678358\">[PubMed 22678358]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3994":"<p><b>Title</b> Anticoagulants / Dasatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dasatinib may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of bleeding or hemorrhagic events. As dasatinib therapy is associated with thrombocytopenia potentially severe bleeding events, extreme caution and vigilence is recommended with concomitant therapy.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Each of these agents possess the potential to cause bleeding. Combined use of these agents would seem to increase that potential. Dasatinib has been shown to cause platelet dysfunction <i>in vitro</i>.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3995":"<p><b>Title</b> Agents with Antiplatelet Properties / Dasatinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dasatinib may enhance the anticoagulant effect of Agents with Antiplatelet Properties. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of bleeding or hemorrhagic events. As dasatinib therapy is associated with thrombocytopenia and potentially severe bleeding events, extreme caution and vigilence is recommended with concomitant therapy.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Each of these agents possess the potential to cause bleeding. Combined use of these agents would seem to increase that potential. Dasatinib has been shown to cause platelet dysfunction <i>in vitro</i>.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3996":"<p><b>Title</b> Zidovudine / DOXOrubicin (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> DOXOrubicin (Conventional) may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Conventional) may diminish the therapeutic effect of Zidovudine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of doxorubicin and zidovudine should be avoided.<sup>1,2</sup> Reduced efficacy of zidovudine is possible (<i>in vitro</i> data). Also, increased myelosuppressive effects are possible with combined administration.</p> \n<p><b>Discussion</b> <i>In vitro</i> data demonstrate the ability of doxorubicin to inhibit the phosphorylation process that is responsible for converting zidovudine to an active antiviral product within cells.<sup>1,2</sup> The effectiveness of zidovudine during concomitant use may be reduced. Further, the myelosuppressive effects of each agent may be additive, or possibly synergistic, leading to greater hematologic toxicity. The concurrent use of these agents is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Retrovir [package insert]. Research Trianlge Park, NC: GlaxoSmithKline, 2006.</p>\n<p>2. Hoggard PG, Veal GJ, Wild MJ, et al, “Drug Interactions with Zidovudine Phosphorylation In Vitro,” <i>Antimicrob Agents Chemother</i>, 1995, 39(6):1376-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7574535\">[PubMed 7574535]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3997":"<p><b>Title</b> Aliskiren / AtorvaSTATin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AtorvaSTATin may increase the serum concentration of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased adverse effects, including augmented hypotensive effects, if aliskiren is used concomitantly with atorvastatin.</p> \n<p><b>Discussion</b> Aliskiren prescribing information states that coadministration of atorvastatin with aliskiren resulted in approximate 50% increases in both maximum concentration and AUC of aliskiren under multiple dosing conditions.<sup>1</sup> In a clinical study of healthy subjects, coadministration of atorvastatin (80 mg orally daily) increased the maximum concentration and AUC of aliskiren (300 mg orally daily) by 50% and 47%, respectively.<sup>2</sup> Aliskiren coadministration reduced atorvastatin maximum concentration by 23% without affecting AUC. O-hydroxy-atorvastatin maximum concentration and AUC were reduced by 22% and 11%, respectively, while these parameters were unaffected for p-hydroxy-atorvastatin.<br><br>The exact mechanisms of these interactions are unclear. Atorvastatin inhibition of CYP3A4 mediated aliskiren metabolism, P-glycoprotein mediated aliskiren transport, or both may contribute to increases in aliskiren concentration and exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tekturna (aliskiren). East Hanover, NJ: Novartis Pharmaceuticals Corporation, November 2009.</p>\n<p>2. Vaidyanathan S, Camenisch G, Schuetz H, et al, “Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren,” <i>J Clin Pharmacol</i>, 2008, 48(11):1323-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18784280\">[PubMed 18784280]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3999":"<p><b>Title</b> Furosemide / Aliskiren</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aliskiren may decrease the serum concentration of Furosemide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for reduced diuresis when these drugs are used in combination.</p> \n<p><b>Discussion</b> Furosemide AUC and maximum serum concentration (Cmax) were reduced an average of 28% and 49%, respectively, when furosemide (20 mg daily x 3 days) was coadministered with aliskiren (300 mg daily x 7 days alone, then with furosemide x 3 days) in a study of 22 healthy volunteers.<sup>1,2</sup> The mechanism for and clinical significance of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vaidyanathan S, Bartlett M, Dieterich HA, et al, “Pharmacokinetic Interaction of the Direct Renin Inhibitor Aliskiren with Furosemide and Extended-Release Isosorbide-5-Mononitrate in Healthy Subjects,” <i>Cardiovasc Ther</i>, 2008, 26(4):238-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19035874\">[PubMed 19035874]</a></p>\n<p>2. Prescribing information. Tekturna (aliskiren). East Hanover, NJ: Novartis Pharmaceuticals Corporation, February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}